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 Melioidosis is a fatal infectious disease caused by the Tier 1 Select Agent 
Burkholderia pseudomallei.  Hallmarks of melioidosis include pneumonic disease and 
prominent septicaemic spread.  Both forms of disease are contingent upon the 
bacterium’s intracellular life cycle and particularly on its ability to escape from host cell 
phagosomes.  Upon encountering a host cell, B. pseudomallei is internalized into 
membrane-bound vacuoles from which the bacterium must rapidly escape to the 
cytoplasm in order to replicate and promote its survival.  In the host cytoplasm, B. 
pseudomallei is capable of polymerizing actin for intracellular and intercellular motility 
and spread, lysing the host cell and perpetuating the cycle of infection.  Commonly used 
intranasal and aerosol models to study respiratory melioidosis result in significant upper 
respiratory tract colonization, dramatically altering disease progression.  Accordingly, we 
developed an improved lung-specific instillation approach to deliver bacteria directly into 
mice lungs, coupled with in vivo optical imaging and observed the development of 
	 vi	
disease that closely resembles human melioidosis in mice.  We found that in the absence 
of upper respiratory tract infection, a capsular polysaccharide (CPS) mutant is only 6.8-
fold attenuated. This mutant is unable to spread to secondary sites of infection, consistent 
with the role of capsule in protecting the bacterium from host antimicrobial activity.  
Similarly, a type 3 secretion system cluster 3 (T3SS3) structural mutant is spread 
deficient, yet this mutant is attenuated 290-fold, strongly suggesting that T3SS3 is critical 
for respiratory melioidosis.  Having a strong platform for studying the pathogenesis of B. 
pseudomallei in a mouse model of lung-specific melioidosis, we used transposon 
mutagenesis to comprehensively identify virulence factors required for B. pseudomallei 
lung colonization and spread to the liver and spleen.  Notably, T3SS3, capsular 
polysaccharide and type 6 secretion system cluster 5 (T6SS5) were the major genetic loci 
required for respiratory melioidosis.  A T6SS5 mutant is not attenuated by LD50 
estimations using our lung-specific melioidosis mouse model.  Yet by competition 
analysis T6SS5, T3SS3 and CPS mutants were attenuated, substantiating the requirement 
of these factors for B. pseudomallei infection as previously reported.  These results 
highlight the importance of competition analysis for studying the fitness of distinct 
virulence determinants.  Importantly, T3SS3 was the only virulence determinant 
attenuated by both LD50 analysis and competition studies, corroborating the critical 
requirement of this virulence system for respiratory melioidosis.  B. pseudomallei is a 
facultative intracellular cytosolic bacterium and its ability to survive intracellularly is 
fundamental to mammalian host infection.  Upon B. pseudomallei internalization into 
host cell vacuoles, the bacterium rapidly escapes this compartment by action of the 
T3SS3.  The T3SS3 is required by B. pseudomallei for intracellular survival by 
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translocating protein effectors to the cytoplasm of host cells and mediating the rapid 
escape of the bacterium from phagosomes of these cells.  We hypothesized that effectors 
act in concert to mediate B. pseudomallei’s rapid escape from phagosomes of host cells 
by manipulating host signaling pathways and promoting bacterial survival.  Using a high-
resolution, high-throughput in vivo imaging screening approach we profiled the 
contributions of five of the six B. pseudomallei putative type 3 effectors to the 
bacterium’s rapid phagosome escape.  Effector mutants exhibited distinct temporal 
differences in escape, with bopA inactivation resulting in the most pronounced delay in 
vacuolar rupture, strongly suggesting that BopA directly mediates escape of B. 
pseudomallei from endocytic vesicles.  We confirmed that a previously identified BopA 
host target, the trafficking particle protein C8 (TRAPPC8), colocalized with Burkholderia 
containing vacuoles.  Small interfering RNA knockdown of this protein strongly suggests 
that TRAPPC8 is required for vacuolar membrane stabilization.  These findings 
substantiate the significant role of the T3SS3 and provide a paradigm to study B. 
pseudomallei natural infection processes and potential vaccine and therapeutic targets. 
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BURKHOLDERIA PSEUDOMALLEI AND MELIOIDOSIS  
 
1.1 Identification of Burkholderia pseudomallei 
	
Burkholderia pseudomallei, the causative agent of melioidosis, was first isolated 
by the pathologist Alfred Whitmore and his assistant C. S. Krishnaswami in April 1911 
during a routine post-mortem examination of a morphine addict in the Laboratory of the 
Rangoon General Hospital in Rangoon, Burma [1].  Lung smears from the diseased man, 
identified the bacterium as a Gram-negative, non-motile organism that resembled 
Burkholderia mallei, the etiological agent of glanders, in both shape and size [1, 2].  
Standard bacteriological examinations revealed that the organism isolated from the 
diseased lung yielded an abundant number of bacteria in broth culture after a three-day 
growth period [1, 2].  Curiously, this “rapid and luxuriant growth” in culture was unlike 
that of B. mallei, and male guinea pigs infected via intraperitoneal inoculation with the 
bacterium in question expired without inflammation of the testicles, a hallmark of 
glanders infection in male guinea pigs [1].  Expansion of bacteria isolated from the 
guinea pig bore a motile bacillus, leading Whitmore to hypothesize that the organism 
isolated from both the human and guinea pig lungs was motile in early cultures but lost 
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its motility within a few days [1].  The striking similarities between the human and 
animal cases prompted the investigation of additional post-mortem examinations 
conducted within the past few months.  The bacterium was isolated in 38 separate 
incidents and examinations revealed patches of lung consolidation in the majority of 
victims.  These patches became the hallmark of the unknown bacillus’ pathology [1].  
Thereupon, Whitmore characterized the bacterium as rod-shaped, Gram-negative, non 
acid-fast, displaying bipolar staining by Leishman’s stain [1].  In broth culture, the 
bacillus was capable of rapid, abundant growth under aerobic and anaerobic conditions 
with formation of a thin white surface layer or pellicle and a thick bacterial aggregate 
undermost after extended periods of growth [1, 2].  Further, bacilli in young cultures 
expressed motility of a “serpentine character,” which was later lost [1].  In agar, young 
bacterial colonies appeared moist and translucent, thickening into cream-colored colonies 
and shifting to wrinkled, pink-hued colonies after extended periods of growth [1, 2].  
Characterization of the unknown organism led Whitmore to propose the name of Bacillus 
pseudomallei for the deadly bacterium [1].  
In 1913 and 1917, investigations by A.T. Stanton and William Fletcher into 
several human infections and what was thought to be a distemper outbreak in mice at the 
Institute for Medical Research in Kuala Lumpur, Malaysia, isolated the same bacterium 
[2].  The cause of these outbreaks was again mistakenly concluded to be B. mallei, as 
clinical manifestations of B. pseudomallei pathology closely resembled those seen in 
glanders patients.  Yet in 1917, Stanton concluded that the illness of animals and man in 
Kuala Lumpur was caused by B. pseudomallei [2].  In 1921, Stanton and Fletcher wrote 
an account of their experiences with the malady and proposed to rename the organism 
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Bacterium whitmori in honor of Whitmore, who first isolated and characterized the 
bacillus [2].  Further, the physicians proposed the name Melioidosis for the illness, for 
ancient Greek physicians referred to maladies that resembled (“eidos”) distemper of asses 
as “melis” [2, 3].  But since its discovery the bacterium has been reclassified into 
numerous genera, Malleomyces in 1939 [4], Pseudomonas in 1957 [5] and finally 
Burkholderia in 1992, when Yabuuchi et al. proposed the transfer of seven bacterial 
species to the new Burkholderia genus based on 16S rRNA sequences, DNA-DNA 




Burkholderia pseudomallei is an environmental free-living organism commonly 
found in the soil and stagnant water in endemic areas [7].  Scant human cases in Burma, 
Kuala Lumpur and Singapore marked the discovery of B. pseudomallei, the causative 
agent of melioidosis [1, 2, 8].  Years after the initial discovery of melioidosis, 
Krishnaswami and Knapp reported that B. pseudomallei had been isolated in 
approximately 5% of post-mortem bacteriological examinations conducted at Rangoon 
General Hospital [8].  Environmental surveys conducted in Malaysia, Singapore and 
Thailand revealed B. pseudomallei’s expansive prevalence in soil and water sources in 
the region [8].  In Java, Indonesia awareness of melioidosis led to an increase in case 
reports in humans and wild animals [8].  Around the same time, China, Hong Kong, 
Korea, the Philippines and Sri Lanka also began to report endemic cases of melioidosis 
[8].  And in Vietnam, the first case of melioidosis was confirmed in 1925 [8].  
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Importantly, the Vietnam War brought great notoriety to the disease in the region.  
Interest in melioidosis arose in the United States and Europe, as a result of military 
service men fighting in Southeast Asia becoming ill with the malady during and after the 
conflict [9].  It was estimated that approximately 225,000 American service members 
were exposed to B. pseudomallei during the war, based on seroconversion studies [10].  
Around the same time in Thailand, increased awareness also shed light into the 
prevalence of the disease in the region, with a 29.1% B. pseudomallei seroconversion rate 
in healthy Thais reported in 1962 [8].  It has been estimated that one in five children 
under the age of 14 fall ill to melioidosis with a 51% mortality rate [11].  Alarmingly, 
current studies estimate that a large number of healthy individuals in the region have 
antibodies against B. pseudomallei by the age of 4 years and that the bacterium is 
responsible for up to 20% of community acquired septicaemia with an associated 50% 
mortality rate in the region [3, 11-13]. 
In northern Australia, the mortality rate associated with melioidosis is significant 
at approximately 20% [3, 10].  Striking figures from several studies showed that males 
are at great occupational risk as 69% of melioidosis patients were males involved in 
farming activities [10].  Approximately 39% of patients suffered from diabetes mellitus 
and 81% of all infections were contracted during the wet season [10].  Diabetes mellitus 
represents the highest pre-existing risk factor associated with melioidosis patients [13].  
Surprisingly, the lack of pre-existing risk factors prior to infection with the bacillus was 
the sole “strongly predictive of survival” [10].  To date, B. pseudomallei infection is the 
“most common cause of fatal community-acquired septicaemic pneumonia in northern 
Australia” [3]. 
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In Central and South America, sporadic cases of melioidosis have been reported 
more recently in El Salvador, Panama, Ecuador and Brazil [8, 14].  In Brazil, numerous 
outbreaks of melioidosis have been reported and the bacterium has been isolated from 
river water and mud, strongly suggesting that B. pseudomallei may be endemic to eastern 
coastal regions of the country [14].  Yet, unavailability of adequate diagnostic methods 
and the lack of familiarity with the disease in Latin American countries may lead to 
melioidosis being under-diagnosed in this region.  In North America, the etiology of most 
melioidosis cases reported can be traced back to recreational or occupational travel to 
melioidosis endemic regions [14, 15].  In the United States, only five melioidosis cases 
have been reported with no history of travel to endemic regions, yet multi-locus sequence 
typing traced back the origins of three of these strains to Southeast Asia [16].  In addition, 
a great number of melioidosis cases were reported in veterans of the Vietnam War, which 
presented with acute febrile illness years after arriving back in the United States 
following the armed conflict [14].  Surprisingly, the longest disease-free interval recorded 
was 62 years for a veteran of the Pacific War [14].  In 2014, two cases of B. pseudomallei 
infection were reported in domesticated animals imported from Central America to the 
United States, thus the bacterium is also capable of persisting in animals years after initial 
infection [17].  Melioidosis is believed to be under-diagnosed in Central and South 
America, where incidence of the disease is mainly observed in rural and remote 
communities.  Accordingly, improvements of rapid diagnostic methods and increased 
clinical awareness may be imperative for accurate identification, treatment and 
prevention of B. pseudomallei in this region [14]. 
Finally, melioidosis incidence not only in Southeast Asia and northern Australia, 
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but endemic pockets in the Middle East, Africa and Central and South America resolved 
that B. pseudomallei is likely native to the world’s tropical and subtropical regions 
located between 20° N and 20° S of the Equator (Figure 1), however the increase of 
animal and plant exports from endemic regions to other parts of world, strongly suggests 
that exposure of the bacterium to other parts of the world may be on the rise [3, 9, 18].  
 
1.3 Clinical Melioidosis 
	
Infection with B. pseudomallei is primarily acquired through percutaneous 
inoculation via skin abrasions during occupational or recreational exposure to the 
bacterium, inhalation of organisms in aerosolized dust or water predominantly during 
heavy rain periods and ingestion [7, 10, 19].  The incubation period of melioidosis is 
approximately1-21 days, with a mean incubation period of just 9 days [10].  Factors 
influencing the morbidity and mortality associated with B. pseudomallei infection 
include: host risk factors such as diabetes mellitus, alcoholism and renal disease, 
infectious dose, route of infection and virulence associated with the infecting B. 
pseudomallei strain [10].  In Australia, a vast majority (~85%) of reported melioidosis 
cases were acute in nature; with symptoms lasting less than 2 months and 11% of cases 
were chronic, with symptoms exceeding 2 months [10].   
During infection, B. pseudomallei can be isolated from the blood, sputum, urine 
and superficial lesions of patients for diagnosis of culture-confirmed melioidosis [2].  The 
bacillus spreads through the blood stream very early in infection, which is supported by 
the septicaemic nature of melioidosis in guinea pigs [2].  Lung infection seems to be an 
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early event in the course of the disease [2], with autopsy results of fatal melioidosis cases 
showing patches of pale and caseous lung consolidation as a hallmark of the disease [1, 2, 
20].  Further, B. pseudomallei is capable of causing focal lesions in every organ of the 
body with exception of the gastrointestinal tract and lymphatic system [9, 20].  Infection 
of the liver and kidneys with presentation of small caseous and necrotic patches of 
haemorrhagic zones and enlarged and softening of the spleen are also considered 
hallmarks of melioidosis [1, 2].  Transmission of melioidosis from person to person is 
unusual, only one case of perinatal transmission and one case of sexual transmission have 
been documented [3] and infection from animals to humans have never been reported [9]. 
Melioidosis manifestations take a vast array of forms and diagnosis may be 
impossible in early stages [2].  Accordingly, the malady has been termed “the great 
mimicker” [11].  Stanton and Fletcher likened melioidosis manifestations to those seen in 
malaria, enteric fever or tuberculosis, cholera, syphilis, plague, typhoid fever, mycosis, 
delirium, acute rheumatism and amoebic abscesses of the liver [2, 9].  Clinical 
presentations can range from asymptomatic seroconversion, acute or chronic pneumonia, 
genitourinary infection, osteomyelitis, localized skin, hepatic and spleen abscesses, 
neurological complications and fulminant septicaemic disease, which is the deadliest 
form of the illness [11, 13].  A recent report correlated the route of B. pseudomallei 
infection with presentations of bacteremia or pneumonic disease [21], finding that 
percutaneous inoculation is negatively associated with bacteremia, ingestion is associated 
with bacteremia and inhalation of the bacterium is associated with pneumonic disease 
[21].  Although, the primary route of inoculation with the bacterium in endemic areas 
occurs through percutaneous exposure, a shift to inhalational infection as the predominant 
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route of inoculation may occur during the rain season, as evidenced by the increase in 
incidence of melioidosis cases [16, 22, 23].  Yet, pneumonic disease remains the most 
common disease presentation in studies of melioidosis patients, with up to 90% mortality 
associated with septic shock from acute melioidosis pneumonia [16].  
Antibiotic treatment of melioidosis is extremely limited due to the bacillus’ 
intrinsic resistance to many classes of antibiotics commonly used to treat bacterial 
infections such as macrolides, beta-lactams, aminoglycosides and polymyxins [9, 13].  B. 
pseudomallei encodes for multidrug efflux systems on chromosome 2 given that the 
bacterium does not carry any plasmids [11], suggesting that antibiotic resistance 
promotes the bacterium’s environmental survival and that these drug resistance 
determinants have not been recently acquired nosocomialy, as is common for other 
multidrug resistant pathogens. 
Melioidosis treatment for culture-confirmed cases includes a lengthy biphasic 
course of antibiotic therapy, divided into an acute phase and an eradication phase of 
treatment [16, 24].  In the acute phase of treatment, the recommended therapy is 
continuous infusion or intravenous administration of the β-lactam ceftazidime for 
approximately 7-28 days with the goal of bacteremia eradication [24, 25].  Alternate 
treatment of severe melioidosis patients with meropenem, showed that this antibiotic may 
be more efficient for the treatment of severe melioidosis, but comparative studies 
between the efficacy of ceftazidime and the latter are not available [26].  In the 
eradication phase, patients are treated with oral trimethoprim-sulfamethoxazole for 
approximately 12 to 20 weeks, with the goal of eradicating surviving B. pseudomallei and 
avoiding recrudescence of the bacillus [24, 27].  However, relapse after apparent 
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clearance of the bacillus is common.  Accordingly, melioidosis was termed the “time 
bomb disease” for its ability to recrudesce many years post latency, with 62 years being 
the longest reported quiescence period after initial infection [8, 10].   Nevertheless, 
approximately 25% of patients with intermittent melioidosis are newly infected with a 
different B. pseudomallei strain rather than relapsing from initial infections [13, 24, 28].   
For individuals who may be at risk of occupational exposure to B. pseudomallei, 
such as laboratory workers, the recommended post exposure prophylaxis include oral 
trimethoprim-sulfamethoxazole as the primary antibiotic cocktail of choice if the patient 
has no documented allergies to either drug and the infectious B. pseudomallei strain is 
susceptible to the antibiotics [29].  In cases of documented allergies or antibiotic 
resistance, doxycycline or amoxicillin-clavulanic acid may be administered, but 
doxycycline treatment alone is associated with higher relapse rates of infection and 
treatment failure, and amoxicillin-clavulanic acid has been shown to be more efficient in 
the treatment of naturally acquired melioidosis [29]. 
 
1.4 Burkholderia pseudomallei genetics 
	
B. pseudomallei’s remarkable genomic plasticity facilitates its ability to inhabit 
diverse niches, as horizontal gene acquisition has played a significant role in the 
evolution of the pathogen’s genome [30, 31].  The bacterium’s genome is one of the 
largest, genetically diverse genomes sequenced to date [11, 30, 32].  The 7.25-megabase 
B. pseudomallei genome is comprised of a 4.07-megabase large chromosome, 
chromosome 1, and a smaller 3.17-megabase chromosome, chromosome 2, [11] with 
approximately 6,332 protein-coding sequences [32].  Sequences in chromosome 1 encode 
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for proteins considered core to the B. pseudomallei genome, these are required for growth 
and metabolism functions such as macromolecule metabolism, nucleotide and protein 
biosynthesis, amino acid metabolism, chemotaxis and motility, among other components 
with shared genetic order in other prokaryotes [31, 32].  Chromosome 2 primarily 
encodes for proteins with accessory functions for adaptation and survival in different 
environments such as secondary metabolism, osmotic protection, iron acquisition, 
horizontally acquired DNA, hypothetical proteins and other components associated with 
plasmid replication, but with little to no conserved genetic order is shared with other 
prokaryotes [2, 32].  The smaller replicon also contains coding sequences critical for 
growth and metabolic functions, such as tRNA genes, an rRNA gene cluster and 
components of the replication and trasnscription machineries, thus chromosome 2 is 
classified as a chromosome rather than a megaplasmid [11].  Approximately 80 to 86% of 
the B. pseudomallei core genome distributed between both chromosomes is homologous 
among more than 111 B. pseudomallei clinical, environmental and animal isolates [11, 
12, 31, 32], and of the core genome, ~8% of genes are considered essential [33].  Clinical 
isolates of the bacillus cluster together in phylogenetic trees based on genomic 
variability, which is suggestive of differential virulence potential among different isolates 
[12].  Although the B. pseudomallei large chromosome shares discrete regions of 
conserved genetic order with the large chromosome of other pathogens such as R. 
solanacearum, the smaller chromosome does not share conserved gene order, strongly 
suggesting differential ancestry for the smaller chromosome [11]. 
Genomic or pathogenicity islands, which are regions of DNA likely acquired 
through horizontal gene transfer, are variably found in clinical B. pseudomallei strains 
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and other pathogenic bacteria and are often associated with virulence in many bacterial 
pathogens [34].  The B. pseudomallei genome contains 16 genomic islands, 12 in 
chromosome 1 and 4 in chromosome 2, which make up ~6.1% (~4.4 Kb) of the 
bacterium’s genome, consistent with the principle that genomic or pathogenicity islands 
occupy large genomic regions in pathogenic bacteria [11, 34].  B. pseudomallei’s fitness 
in diverse niches is reasoned to be directly mediated by the bacterium’s genetic plasticity 
and diversity supplemented in part by genomic islands [12, 32] and the presence of these 
genomic islands in B. pseudomallei clinical isolates suggest that these regions may play 
key roles in the bacterium’s virulence by predisposing these strains to cause disease in 
humans [12].   
 
1.5 Burkholderia pseudomallei intracellular life cycle 
 Following internalization into target cells B. pseudomallei is contained within 
membrane-bound vacuoles, followed by bacterial escape into the cytoplasm [35].  
Following escape of the bacterium from endocytic vesicles, B. pseudomallei is free to 
replicate in the cytoplasm of host cells, polymerizing actin at one pole resulting in 
intracellular motility and intercellular spread, eventually lysing the host cell (Figure 2). 
Vacuoles containing B. pseudomallei T3SS3 mutants incapable of vacuolar escape 
colocalize with the lysosome marker LAMP-1 and with the autophagy marker LC3 [36].  
However, T3SS3 mutant-containing vacuoles do not possess the double membrane 
characteristic of autophagosomes, suggesting that B. pseudomallei infection does not 
trigger autophagy in host cells [36].  Alternatively, it has been proposed that LC3 may be 
recruited to T3SS3 mutant-containing vacuoles through LC3-associated phagocytosis, 
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resulting in decreased bacterial survival [37].  Accordingly, vacuolar escape is critical for 
the bacterium’s intracellular lifestyle, thus this process must occur rapidly following 
internalization.  The precise time B. pseudomallei escapes from vacuoles remains 
unknown, yet the kinetics of vacuolar escape of other cytosolic pathogens such as 
Francisella tularensis, Shigella flexneri, Listeria monocytogenes and Rickettsia spp. 
range from 15 to 60 minutes post internalization, suggesting that B. pseudomallei escapes 
phagosomal vesicles in a comparable time frame [35].  Vacuolar escape of cytosolic 
pathogens is a bacterial-driven process and for B. pseudomallei the T3SS3 mediates this 
event (discussed in section 1.6.3) [38].  
 
1.6 Burkholderia pseudomallei virulence determinants 
Characteristics of melioidosis such as difficulty in treating infection and instances 
of prolonged quiescent periods after initial infection followed by relapse years later, 
suggest that B. pseudomallei is a facultative intracellular pathogen [39-41].  Further, the 
bacterium is capable of surviving and replicating within human polymorphonuclear 
leukocytes, monocytes and phagocytic and non-phagocytic cultured cells [39-41].  B. 
pseudomallei and other pathogenic bacteria possess the ability to cause disease in humans 
through the use of virulence factors that allow the bacteria to successfully overcome host 
immune mechanisms.  Key B. pseudomallei virulence factors include the capsular 
polysaccharide (CPS), type 6 secretion system (T6SS), type 3 secretion system (T3SS), 
quorum sensing, lipopolysaccharide, flagellin, type 2 secretion system, type 4 pili and 
phospholipase C among other undescribed factors [7].  These virulence systems are 
required for different aspects of B. pseudomallei host intracellular, extracellular and 
	 13	
environmental survival, herein we concentrate on T3SS3, CPS and T6SS5, which are the 
focus of our studies. 
 
1.6.1 Type 3 Secretion Systems  
The type 3 secretion system is a needle-like apparatus that translocates effector 
proteins across both Gram-negative bacterial membranes into the cytoplasm of eukaryotic 
cells [42, 43].  The Gram-negative type 3 machinery is made up of ~15-20 scaffolding or 
structural proteins that make up the basal body that spans both bacterial membranes, and 
the secretion apparatus or needle that delivers effectors to its host target [7, 42, 44].  In its 
genome, B. pseudomallei encodes 3 type 3 secretion loci [38, 45, 46].  Clusters 1 and 2 
share homology with the plant pathogens Ralstonia solanacearum and Xanthomonas spp. 
[45] T3SS and cluster 3 (T3SS3) shares homology with the Salmonella typhimurium 
Inv/Spa/Prg and the Shigella flexneri Ipa/Mxi/Spa type 3 secretion systems, required for 
intracellular survival of both pathogens [46].   
The T3SS is critical for the intracellular life cycle and survival of pathogenic 
bacteria such as Shigella spp., Salmonella spp., E. coli, Yersinia spp. and Pseudomonas 
aeruginosa [43].  The intracellular life cycle of B. pseudomallei and other pathogenic 
cytosolic bacteria such as Shigella flexneri consists of escape from host cell vacuoles 
following internalization, replication in the cytoplasm of the host cell (Figure 2) and 
manipulation of host cell signaling pathways that promote the bacterium’s intracellular 
fitness [35].  B. pseudomallei has evolved to rapidly escape from endocytic vacuoles 
through the use of the type 3 secretion system cluster 3 [35].  Upon contact with the 
vacuolar membrane, the B. pseudomallei type 3 secretion apparatus forms a channel 
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between bacteria and host, secreted translocon proteins and the needle tip form a pore in 
the vacuolar membrane translocating very small amounts of effector proteins into the 
cytoplasm of the target cell [42, 44, 47].  B. pseudomallei injects type 3 secretion 
effectors across vacuolar membranes following internalization to rapidly escape to the 
cytoplasm, where the bacteria can continue its life cycle, bypassing killing by the host 
cell and eventually lysing the cell [39].  Translocated effectors may interact with host cell 
proteins facilitating the rapid escape of B. pseudomallei from endocytic vesicles by 
manipulating signal transduction pathways in the cell, promoting bacterial survival and 
spread [43].  Major hallmarks of type 3 secretion effector functions in other bacterial 
pathogens include inhibition of phagocytosis, cytoskeletal rearrangement, mediation of 
escape of the bacterium from host vacuoles, manipulation of cellular signaling pathways 
that promote bacterial survival, down-regulation of host cell inflammatory response or 
inhibition of apoptosis [43]. 
The B. pseudomallei T3SS3 is the only type 3 secretion system of critical 
importance for B. pseudomallei virulence in mammals, as it is the only cluster required 
for virulence in a Syrian golden hamster model of systemic melioidosis [7, 19].  
Conserved type 3 secretion apparatus components were named Sct by Attree and Attree, 
but were later designated bsa (Burkholderia secretion apparatus) by Stevens et al., 
leading to multiple nomenclatures for T3SS3 [38, 46].  A mutant in a component of the 
T3SS3 export apparatus, sctU, exhibits no effector secretion and almost no intracellular 
replication in cultured macrophages when compared to wild type strains, strongly 
suggesting that T3SS3 is critical for intracellular fitness of B. pseudomallei [38, 48].  
This mutant remains trapped in endocytic vesicles of cultured macrophages up to 12 
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hours post infection, although early in infection ~95.1% of bacteria were associated with 
the lysosomal marker lysosome-associated membrane glycoprotein-1 (LAMP-1) [38].  
Actin tail formation, a hallmark of Shigella spp., Rickettsia spp. and L. monocytogenes in 
the cytoplasm of host cells, is also impaired in this mutant, again supporting the 
previously observed escape deficient phenotype of the sctU mutant [38].  These data 
demonstrate that the B. pseudomallei T3SS3 is critical for intracellular survival of the 
bacterium by mediating the bacterium’s rapid escape to the cytoplasm of host cell. 
Translocation of T3SS3 effectors is mediated by a set of translocon proteins and 
the T3SS3 apparatus needle tip termed Burkholderia invasion proteins (Bips), which 
form a pore in the vacuolar membrane of the host cell and include BipB, BipC and BipD 
[19, 38].  The Bip proteins, BipB, BipC and BipD, make up the translocon proteins and 
needle tip, respectively, of the T3SS3 apparatus [44].  BipB and BipC form a pore in the 
eukaryotic host cell membrane, but are also secreted into the cytoplasm; therefore it is 
possible that these translocon proteins may have additional roles during B. pseudomallei 
infection [44].  Accordingly, bipB and bipC mutants exhibit impaired invasion of non-
phagocytic cultured cells and reduced intracellular fitness, strongly suggesting that 
efficient interaction of B. pseudomallei with host cells and efficient delivery of T3SS3 
effectors to the cytoplasm of the cell is required for full virulence of the bacterium [49, 
50].  Notably, inactivation of bipC also leads to delayed escape of B. pseudomallei from 
endocytic vacuoles, leading to a 2-fold reduction in intracellular burden in cultured cells 
[50].  It is possible that inactivation of bipB leads to a similar phenotype, given that 
defective formation of a translocon pore likely leads to inefficient effector delivery, 
compromising the fitness of the bacterium in host cells.  In addition, BipB may also have 
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a role in B. pseudomallei late infection, as it has been shown to be required for efficient 
cell-to-cell spread of the bacterium by promoting fusion of the plasma membrane of cells 
infected with B. pseudomallei and that of neighboring cells [49].  These data suggests that 
other effectors may also be required for optimal cell-to-cell spread by host membrane 
fusion events and that effectors function during early and late events in the infection 
process, yet cell-to-cell spread by membrane fusion has only been observed during B. 
pseudomallei in vitro infection of cultured cells, so whether cell-to-cell spread by fusion 
events take place in vivo remains unknown [49].  Lastly, both bipB and bipC mutants are 
significantly attenuated in an intranasal BALB/c model of respiratory melioidosis, 
validating the requirement for formation of a translocon pore for full B. pseudomallei 
virulence in mammals [49, 50].  Thus taken together, these data suggest that efficient 
formation of a translocon pore by B. pseudomallei T3SS3 translocon proteins is required 
for adherence, invasion, translocation of effectors and overall fitness of B. pseudomallei 
in mammalian infection. 
BipD the tip of the T3SS3 needle is also required for the efficient and timely 
delivery of effector proteins, stalling secretion in the absence of host cell contact [44].  
Consequently, inactivation of bipD renders the bacterium incapable of efficient escape 
from endocytic vesicles, impaired intracellular replication and decreased intracellular 
survival in cultured macrophages, consistent with the phenotypes observed for bipB and 
bipC mutants, which make up the translocon pore [50, 51].  Crystal structures of BipD 
and its Shigella homologue IpaD, suggest that BipD may play a role as an extracellular 
chaperone, by guiding and mediating the insertion of BipB and BipC into the host cell 
membrane and by potentially tethering the translocon pore to the T3SS needle [51].  
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Notably, the crystal structure of BipD shows that the protein contains a highly conserved 
region at its C-terminal end that may be involved in protein-protein interactions with the 
translocon pore [51, 52].  Importantly, purified BipD, as well as BipB and BipC, strongly 
react with serum from convalescent melioidosis patients and other T3SS3 components 
have been successfully used in experimental vaccines in animal models, strongly 
suggesting that these proteins may constitute potential therapeutic and vaccine candidates 
[38].  Yet, vaccination of BALB/c mice with purified BipB, BipC or BipD did not confer 
immune protection against intraperitoneal challenge with wild type B. pseudomallei 
protein, suggesting that these proteins may be secreted in very low amounts or that host 
antibodies may not have access to these proteins as B. pseudomallei is a facultative 
intracellular pathogen [53]. 
B. pseudomallei effector proteins were named Burkholderia outer proteins or 
Bops and constitute BopA, BopC and BopE, named in a similar manner to Salmonella’s 
outer proteins [19, 38].  The Burkholderia secretion apparatus (Bsa) associated proteins 
or Baps (BapA, BapB and BapC), have no known function as of yet in type 3 secretion 
[19, 38], although recent studies confirmed that BapA [54, 55] and BapC [55] are 
secreted in vitro in a T3SS3-dependent manner, suggesting that the Bap proteins may 
contribute to the intracellular survival of the bacterium in host cells.  Bop and Bap T3SS3 
effector proteins are translocated into the cytoplasm of host cells by the T3SS3 apparatus 
during infection [19, 38].   
The Burkholderia outer proteins, BopA, BopC, BopE, BapA and BapB are the B. 
pseudomallei T3SS3 putative translocated effectors, which most likely contribute to 
replication, survival, spread and ultimately persistence of the bacterium within its host.  
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BopA is critical for the rapid escape of B. pseudomallei from endocytic vacuoles of 
cultured macrophages, as bopA mutants exhibit delayed escape from RAW264.7 
phagosomes, demonstrating that BopA directly mediates vacuolar rupture in cultured 
phagocytic cells [36].  In addition, the vacuole containing this mutant co-localizes with 
the autophagy marker microtubule-associated protein light chain-3 (LC3) and the 
lysosome marker LAMP-1 for longer periods of time than the wild type vacuole, leading 
to increased killing by LC3-associated phagocytosis and subsequent decreased 
intracellular replication in cultured macrophages [36].  Yet the bopA mutant does not 
trigger cellular autophagy, rather reduced intracellular bacterial numbers during infection 
are a result of delayed escape of the mutant into the cytoplasm, confirmed by electron 
transmission microscopy [36].  In addition, the bopA mutant is capable of inducing actin 
tail formation at later times during infection, supporting the previously observed delayed 
escape phenotype [36].  Further studies are needed to demonstrate the mechanism by 
which BopA mediates vacuolar escape and other potential contributions of this effector to 
the intracellular life cycle of the bacterium. 
BopE is also secreted in a T3SS3-dependent manner in vitro [48].  Consistent 
with phenotypes observed with inactivation of its Salmonella-homologues SopE and 
SopE2, which promote bacterial invasion of non-phagocytic cells, inactivation of bopE is 
associated with significant reduction in invasion of HeLa cells [48].  Yet, B. pseudomallei 
is only weakly invasive when compared to Salmonella and is phagocytosed into cells 
rather than promoting its own uptake [39].  BopE is an effective guanine nucleotide 
exchange factor (GEF) for the SopE and SopE2 mammalian target proteins Cdc42 and 
Rac1, but with a lower exchange rate, suggesting that BopE may target other host 
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GTPases and may be required for effector functions other than invasion of host cells [48].  
Notably, the invasion rate of B. pseudomallei in numerous epithelial and fibroblast cell 
lines is low compared to invasive Salmonella, again suggesting that Cdc42 and Rac1, 
which are involved in cytoskeleton rearrangement, are not targeted by B. pseudomallei 
for invasion.  In a similar manner, BopC in vitro secretion is dependent on a functional 
T3SS3 apparatus and inactivation of this effector is also associated with reduced invasion 
of the human A549 epithelial cell line [56].  But, very little data is available on the 
functions of BopE and BopC during infection, thus further studies to discern the 
contributions of these effectors to the B. pseudomallei intracellular life cycle are of 
pressing concern, as no role has been attributed to either effector during infection of host 
cells.  Overall, these data strongly suggest that a functional B. pseudomallei T3SS3 and 
efficient delivery of T3SS3 protein effectors is critical for the pathogenesis of the 
bacterium in host cells.  Specifically, T3SS3 is critically required for efficient adherence, 
invasion, rapid vacuolar escape and intracellular fitness, promoting and mediating the 
survival of B. pseudomallei in mammalian hosts.  Importantly, translocation of effectors 
and interaction of these effectors with host proteins, as evidenced by S. flexneri and S. 
enterica T3SS3 effectors, promotes intracellular fitness of B. pseudomallei.  Accordingly, 
extensive studies are needed to elucidate the individual contributions of type 3 effectors 
to the intracellular life cycle of B. pseudomallei in efforts to find potential vaccine targets 
or therapeutics against B. pseudomallei infection. 
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1.6.2 Capsular Polysaccharide   
The capsular polysaccharide makes up the outermost layer of Gram-negative bacterial 
cells.  It is composed of highly hydrated homo- or heteropolymers of repeating 
monosaccharides joined together by glycosidic bonds in distinct numbers of 
configurations, resulting in highly diverse capsular structures synthesized by different 
bacterial species [57].  Capsule production has been associated with virulence in bacteria 
that cause serious human diseases, given that capsule mediates interactions between 
bacterial cells and their environment [58].  As a result, the capsular polysaccharide is 
characterized as a key virulence determinant for many pathogenic bacteria [57].  
Importantly, the bacterial capsule has been implicated in protecting the bacterial cell 
against desiccation, promoting transmission and survival, adherence to target cells, 
resistance to opsonophagocytosis and protection against complement-mediated lysis and 
host specific immunity [59, 60].   
The B. pseudomallei genome contains 4 operons (CPS I-IV) with genes predicted 
to be required for biosynthesis and export of 4 different capsular polysaccharides [58].  
CPS I encodes a capsular polysaccharide similar to that produced by the human 
pathogens Escherichia coli, Haemophilus influenzae and Nisseria meningitidis [59, 61].  
Genes with predicted biosynthetic functions in this operon share homology to genes 
required for synthesis of structures primarily composed of mannose, and genes with 
predicted functions in polysaccharide export share homology to those found in various 
bacterial species that serve the same function [58].  G+C content of this operon is ~58%, 
substantially lower than the 68% G+C content in the rest of the genome, suggesting 
potential acquisition of this operon through horizontal gene transfer [58].  The CPS I 
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operon is also found in B. mallei, a host adapted clone of B. pseudomallei that is 
pathogenic to mammals [58].  In contrast, CPS II, CPS III and CPS IV are also found in 
the B. pseudomallei avirulent relative Burkholderia thailandensis but not in B. mallei 
[58].  Accordingly, the CPS II, III and IV loci do not contribute to the virulence of B. 
pseudomallei in mammals, strongly suggesting that these loci may be required for 
environmental fitness of the bacterium [58].  
To date, the B. pseudomallei the CPS I operon is one of the most important 
virulence determinants required for the bacterium to cause systemic melioidosis [59], 
given that capsule protects B. pseudomallei against specific and non-specific host 
immunity [58].  Capsular polysaccharide glycosyltransferase and mannosyltransferase 
genes are both required for production of major surface polysaccharides [61] and mutants 
in both genes exhibit up to 10,000-fold attenuation in an intraperitoneal hamster model of 
systemic melioidosis and a mouse model of acute melioidosis, respectively, corroborating 
the importance of capsule for B. pseudomallei virulence [59, 62].  Further, capsule is 
required for B. pseudomallei persistence in the blood by reducing complement factor C3b 
deposition on the bacterial surface and by protecting the bacterium from phagocytosis by 
polymorphonuclear leukocytes, which is consistent with the role of the capsular 
polysaccharide in E. coli [59, 63].  Glycosyltransferase mutants are incapable of 
colonizing the lung, liver and spleen of hamsters in a systemic model of melioidosis, 
highlighting the importance of the capsule for establishing systemic disease [59].  In a 
similar manner, the mutant strain JW270, which is missing the entire capsular 
polysaccharide operon, is attenuated ~2 log in an intranasal mouse model of acute 
melioidosis and is incapable of colonizing the blood at similar levels than the isogenic 
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parental strain, consistent with the requirement of capsule for B. pseudomallei persistence 
in the blood previously observed [60].  Yet, this mutant is capable of colonizing the lung 
and liver at similar levels to that of the parental strain, and the spleen at lower levels 
during lethal challenge, yet tissue damage to the liver and spleen is less severe than that 
of the isogenic parental strain, suggestive of an altered host immune response against 
acapsular bacteria [60].  These results also suggest that the B. pseudomallei capsular 
polysaccharide may not play the same critical role for the bacterium for pneumonic 
disease relative to its critical role for systemic disease.  
In vitro, acapsular JW270 is internalized and capable of intracellular replication 
and survival within cultured macrophages up to 9 hours post infection at levels similar to 
those of the isogenic parental strain [60].  These results strongly suggest that the B. 
pseudomallei capsule is not antiphagocytic for macrophages in the absence of 
opsonization [60].  Bioluminescent detection of an isogenic acapsular light producing 
strain in infected macrophages showed a reduction in bacterial burdens of this mutant 
when compared to the parental strain at late stages of macrophage infection (>9 hours 
post infection), strongly suggesting that capsule is dispensable for early stages of 
macrophage infection [64].  Overall, these results highlight the importance of capsule as a 
virulence determinant for systemic fitness of B. pseudomallei in mammalian hosts and 
that genes required for capsular polysaccharide biosynthesis may be considered potential 
therapeutic and vaccine targets for systemic disease. 
 
1.6.3 Type 6 Secretion Systems  
Type 6 secretion systems (T6SS) are bacterial virulence-associated injectisomes 
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that translocate effector proteins into target eukaryotic or prokaryotic cells [65].  T6SS 
are found in the genomes of ~25% of all sequenced Gram-negative bacteria and have 
been implicated in cell-to-cell contact killing during host cell invasion and during inter-
bacterial community competition [65-67].  The T6SS is comprised of ~15-20 open 
reading frames encoding various apparatus components that are structurally homologous 
to the components of the bacteriophage tail [68].  The apparatus is comprised of a base 
plate complex that spans the inner and outer bacterial membranes and a bacteriophage 
tail-like injectisome, it is highly dynamic and is hypothesized that it may be driven by a 
phage tail-like contraction mechanism [65, 68].  Assembly of the base complex initiates 
the polymerization of the injectisome inner tube protein Hcp and the outer phage tail-like 
sheath made up of the ClpV-interacting proteins A and B (VipA and VipB) in an 
extended conformation [65].  An unknown stimulus causes the contraction of the 
VipA/VipB sheath leading to translocation of effector proteins to neighboring cell targets 
and secretion of the tail spike protein VgrG and Hcp tubule [65].  Activity of the AAA+ 
ATPase ClpV is critical for disassembly of the contracted sheath in the cytoplasm of the 
bacterial cell and apparatus components are recycled for use in de novo machinery 
assembly [67]. 
 The B. pseudomallei genome encodes for six evolutionary distinct T6SS 
comprising ~2.3% of the bacterium’s genome, strongly suggesting that these systems 
play key roles in the fitness of B. pseudomallei in diverse environments [66, 69].  Type 6 
secretion phylogenetic trees show that the only B. pseudomallei type 6 locus that clusters 
with eukaryotic cell targeting systems, such as those found in Vibrio cholerae and 
Aeromonas hydrophila, is cluster 5 (T6SS5) and that the remaining loci cluster with 
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bacterial cell targeting systems such as those found in Pseudomonas aeruginosa [66].  
Importantly, T6SS5 is the only locus demonstrated to have a critical role during 
mammalian virulence [66].   
Secretion of the T6SS inner tube needle protein Hcp is a hallmark of a functional 
type 6 secretion system [70].  Importantly, recombinant Hcp5 but not Hpc1, -2, -3, -4 or -
6, strongly react with sera from melioidosis patients, suggesting that only T6SS5 is 
expressed during B. pseudomallei human infection and that this protein is highly 
immunogenic [70].  Expression of the B. pseudomallei VirAG two-component regulon in 
trans results in transcriptional activation of T6SS5 and secretion of Hcp5 in RAW264.7 
macrophages [70].  The T6SS5 genes tssM, tssI and tssH are expressed in B. 
pseudomallei during growth in macrophages, demonstrating that cluster 5 encodes a 
functional type 6 secretion apparatus expressed in vivo [69].  In addition, an hcp5 mutant 
is ~1000-fold attenuated in a Syrian hamster model of systemic melioidosis, but not hcp1, 
-2, -3, -4 or -6 mutants, again demonstrating that T6SS5 is a major virulence determinant 
for B. pseudomallei for systemic melioidosis and that the other T6SS clusters may be 
required for bacterial survival in environmental niches.  Vaccination of BALB/c mice 
with recombinant Hcp1, -2, -3, -4, -5 or -6 showed that the recombinant proteins elicit 
specific antibody responses in mice, but the immune responses elicited were not 
protective, suggesting that individual proteins alone may not constitute strong vaccine 
candidates, but may be targeted for diagnostic testing of B. pseudomallei infection [70].   
In RAW264.7 cultured macrophages, an hcp5 mutant exhibits a significant intracellular 
fitness defect and reduced cytotoxicity [70].  This result contrasts with previous 
observations, which showed that a mutant in the tssH-5 gene, a homolog of the AAA+ 
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ATPase ClpV is as fit as a wild type strain in the same cell line, yet it is possible that if 
intracellular bacterial burdens would have been quantified at more than two time points, 
then the intracellular fitness defect of the mutant would have been noticeable [69].  
A mutant in the tag-AB gene, encoding a hypothetical protein located in the T6SS5 locus, 
is highly attenuated in an intranasal BALB/c model of respiratory melioidosis [71].  And 
in vitro a tag-AB mutant exhibits an intracellular fitness defect in both RAW264.7 cells 
and the human lung epithelial cell line A549 [71].  Importantly, inactivation of tag-AB 
leads to a pronounced defect in Hcp5 export, strongly suggesting that tag-AB is critical 
for expression of functional T6SS5 machinery.  Thus, taken together, these results 
highlight the importance of T6SS5 to the intracellular lifestyle of B. pseudomallei, yet 
very little is known about the functions of this virulence system inside host cells. 
Significantly, these data demonstrate that T6SS5 is a key virulence determinant for 
systemic melioidosis and that genes in these loci may serve as potential vaccine and 





Figure 1.  Worldwide distribution of Burkholderia pseudomallei endemicity.  B. 
pseudomallei is highly endemic to regions of Southeast Asia and Northern Australia.  
Endemic pockets of melioidosis are also found in Africa and South America.  Regions 
where endemicity of the bacterium is definite, probable and possible are highlighted.  
Current reports indicate that the bacterium may inhabit tropical and subtropical regions 
worldwide located between 20° N and 20 °S of the Equator. 
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Figure 2.  The Burkholderia pseudomallei intracellular life cycle.  B. pseudomallei 
(Bp) is internalized into a membrane-bound vacuole during host cell entry (1).  Inside the 
vacuole, the bacterium translocates effector proteins via the T3SS3 to disrupt the 
vacuolar membrane and rapidly escape into the cytoplasm (2a) or risk getting killed by 
the host cell through vacuole acidification (3b and 4b).  Once free in the cytosol, bacteria 
can replicate (3a) and polymerize actin for intracellular mobility and intercellular spread 
(4a).  These events lead to lysis of the host cell by B. pseudomallei (5a) and 


























































1.7 Specific Aims 
The goal of this dissertation is to define the role(s) of the Burkholderia pseudomallei type 
3 secretion system cluster 3 (T3SS3) in mediating respiratory disease.  Type 3 secretion 
systems are significant contributors to the pathogenesis of numerous Gram-negative 
bacterial species, which utilize this injectisome to subvert host cellular defense 
mechanisms by translocating effector proteins into the cytoplasm of host cells.  The B. 
pseudomallei T3SS3 is an important virulence determinant in both respiratory and 
systemic models of disease.  The T3SS3 system potentially mediates bacterial escape 
from endocytic vesicles of phagocytes by employing its translocated effector proteins.  
However, the overall mechanisms by which B. pseudomallei T3SS3 effectors mediate 
vacuolar escape have not been elucidated.  The results of this research project will further 
our understanding of the pathogenesis of Gram-negative bacteria, particularly on how 
T3SS and its effectors act either alone or in concert to modulate host cellular processes to 
the pathogen’s benefit and importantly may provide vaccine and/or therapeutic targets 
against B. pseudomallei infection.  Accordingly, we hypothesize that the B. pseudomallei 
T3SS3 is one of the most critical virulence determinants in a lung-specific mouse model 
of respiratory melioidosis and that is also critically required for the bacterium’s 
intracellular life cycle.  Herein, we propose 3 Specific Aims to test this hypothesis. 
 
Aim 1. Develop a lung-specific mouse model of respiratory melioidosis.  Hypothesis: 
Lung-specific delivery of B. pseudomallei would provide a more human-like model of 
respiratory melioidosis.  
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A. Compare in vivo disease kinetics of mice inoculated via the intranasal route or via 
intubation-mediated intratracheal (IMIT) instillation. 
B. Determine the course of disease of capsule and T3SS3 mutants in an IMIT mouse 
model of melioidosis. 
 
Aim 2. Identify Burkholderia pseudomallei virulence determinants required for 
respiratory melioidosis and spread to secondary sites of infection.  Hypothesis: A 
human-like model of respiratory melioidosis would identify novel and characterized 
virulence determinants required by B. pseudomallei to cause respiratory melioidosis and 
subsequent dissemination to the liver and spleen. 
A. Create a transposon insertion library in the genome of B. pseudomallei.  
B. Validate the role of virulence determinants identified by the Tn-Seq screen in the 
pathogenesis of B. pseudomallei.  
 
Aim 3. Define the contributions of T3SS3 effectors to the intracellular life cycle of 
Burkholderia pseudomallei.  Hypothesis: T3SS3 effectors mediate B. pseudomallei‘s 
rapid escape from host cell phagosomes by potentially modulating host signal 
transduction pathways. 
A. Assess the kinetics of growth of wild type B. pseudomallei, a T3SS3 structural 
mutant and effector mutants. 
B. Assess the individual contribution of a specific effector in mediating rapid 
escape of B. pseudomallei from host cell phagosomes.
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CHAPTER II 
MATERIAL AND METHODS 
 
 
2.1 Bacterial strains and culture 
	
Burkholderia pseudomallei and Escherichia coli strains were routinely cultured in 
Lennox Broth (LB) at 37°C.  In preparation for infection studies, B. pseudomallei strains 
were subcultured 1:25 from overnight LB cultures into dialyzed and chelated Trypticase 
Soy Broth (TSBDC) [72] supplemented with 50 µM monosodium glutamate and grown 
for 3 hr at 37°C with shaking.  When appropriate, antibiotics were used at the following 
concentrations: kanamycin (Km), 25 µg/ml; polymyxin B (Pm), 50 µg/ml; streptomycin 
(Sm), 100 µg/ml; and gentamicin (Gm), 20 µg/ml.  
 
2.2 Luminescent Burkholderia pseudomallei 
	
Luminescent B. pseudomallei strains JW280 and JW280 Δwcb were generated and 
described elsewhere [73].  JW280 ΔsctUBp3 was generated by allelic exchange by using 
the S17-1/pKAS46-araPtolClux construct [73] to add the luxCDABE operon to DD503 
ΔsctUBp3 [19], as previously described. 
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2.3 Ethics Statement 
	
All animal studies were conducted under Biosafety Level 3 conditions using eight to ten 
week old female albino C57BL/6J mice (B6 (Cg)-Tyrc-2J/J, Jackson Laboratories) bred at 
the University of Louisville (Protocol Number 11113).  These studies were approved by 
the University of Louisville’s Institutional Animal Care and Use Committee (Protocol 
numbers 10073 and 13053), in agreement with National Institutes of Health guidelines 
and the “Guide for the Care and Use of Laboratory Animals” (NRC).   
 
2.4 Mouse respiratory infections 
	
Animal studies were conducted under Biosafety Level 3 conditions using eight to ten-
week-old female or male albino C57BL/6J  mice (B6(Cg)-Tyrc-2J/J, Jackson Laboratories 
and in-house breeding).  Freshly grown bacteria were washed into phosphate buffered 
saline (PBS) to appropriate concentrations for infection using OD600-based calculations.   
Intranasal infections were carried out as previously described using 30 µl B. pseudomallei 
suspensions [60].  Intubation-mediated intratracheal (IMIT) instillation was performed, as 
previously described, to facilitate non-surgical lung-specific disease [74, 75].  Briefly, 
mice were isoflurane-anesthetized and 2% lidocaine was applied to the back of the mouth 
as a local anesthetic.  Mice were intubated using a 20-gauge catheter, and catheter 
placement was confirmed by flow meter.  Bacterial suspensions were directly instilled 
into the lung using a 22-gauge blunt needle inserted through the catheter.  Optical 
diagnostic imaging was conducted with an IVIS Spectrum (Caliper Life Sciences) as 
described previously [73, 76], with once to twice-daily imaging through day 5, and once 
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daily thereafter until the study completion at day 14.  Animals were euthanized at the 
onset of moribund disease, which was defined by loss of righting reflex. 
 
2.5 Bacterial enumeration at key sites of infection 
	
Infected animals were euthanized and necropsied to enumerate bacteria from infected 
tissues.  Blood samples were collected by cardiac puncture, while bronchoalveolar lavage 
(BAL) was collected in 1 ml of PBS.  Necropsied tissues were subjected to 
bioluminescence imaging (IVIS Spectrum) in a 24-well black plate before serial dilution 
enumeration of bacterial burden from tissue homogenate, as described elsewhere [76].  
We have defined correlations between tissue counts per second (cps) and colony forming 
units (CFU) specifically for each tissue as follows: Lung, log(cps) = 1.219log(CFU) – 
2.999 (R2 = 0.68); Liver, log(cps) = 1.238log(CFU) – 3.502 (R2 = 0.99); Spleen, log(cps) 
= 1.088log(CFU) – 1.741 (R2 = 0.98). 
 
2.6 Tn-Seq Library Preparation 
	
Plasmids used in this study are identified in Table 1.  To construct the transposon 
delivery vector pSAM-DKm, the mariner-family transposon, Himar1 C9 transposase and 
its upstream regulatory region were PCR amplified from pBTK30 and cloned as a BamHI 
restriction fragment into pSAM-Bt to yield pSAM-DYH   The kanamycin resistance 
cassette from pEXKm5 was PCR amplified and inserted into the MfeI and XbaI 
restriction sites in place of the erythromycin resistance cassette and the resulting plasmid, 
pSAM-DKm was verified by PCR.  To generate the B. pseudomallei Tn-Seq library, the 
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E. coli S17-1 strain transformed with pSAM-DKm was conjugated with the luminescent 
B. pseudomallei parent strain JW280 for 2 hrs at 37°C.  Transposon mutants were 
selected for on PmKm LB agar plates and grown at 37°C for 24 hrs.  A library of 2x104 
unique mutants were pooled, grown in PmKm LB broth with shaking at 37oC and 
cryopreserved. 
 
2.7 Tn-Seq Screen 
A B. pseudomallei Tn-Seq library TSBDC culture was washed into phosphate buffered 
saline (PBS) and OD600 readings were used to estimate bacterial concentrations in order 
to prepare an inoculum of 104.74 CFU/50 µl.  A group of three mice were inoculated with 
50 µl of bacterial suspension of the Tn-seq library by intubation mediated intratracheal 
(IMIT) instillation, as described [77].  Disease progression was monitored twice daily by 
optical diagnostic imaging of bioluminescent B. pseudomallei until study completion, as 
described [78].  Animals were euthanized at moribund endpoints (66 hrs post infection) 
and necropsied to collect lungs, liver and spleen.  Tissues were homogenized and bacteria 
from these tissues were cultured in LB broth overnight at 37°C with shaking.  
Bioluminescence imaging data was processed as described [77]. 
Chromosomal DNA was purified from triplicate biological samples [79] and pooled for 
each tissue.  Genomic DNA was digested with the MmeI restriction enzyme overnight at 
37°C, treated for 20 minutes at 80°C to inactivate the enzyme, purified using the 
QIAquick, PCR purification kit (Qiagen) according to the manufacturer’s instructions, 
and concentrated with a speed vacuum to a final volume of 30 µl.  Restricted fragments 
were separated by electrophoresis in a 1% agarose gel and fragments corresponding to 
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1.2 to 1.5 Kb were isolated using the QIAquick Gel Extraction Kit (Qiagen).  Fragments 
were ligated to barcoded double stranded adaptors using T4 DNA ligase in 50 µl 
reactions overnight at 16°C, treated at 65°C for 10 minutes to inactivate the ligase, and 
purified using the QIAquick PCR purification kit.  Transposon-genome junctions were 
amplified by PCR using the LIB_PCR_5 (5′-
CAAGCAGAAGACGGCATACGAAGACCGGGGACTTATCATCCAACC TGT-3′) 
and LIB_PCR_3 (5′-AATGATACGGCGACCACCGAACACTCTTTCCCTACAC
GACGCTCTTCCGATCT-3′) primers [80] using HiFi DNA Polymerase (KAPA 
Biosystems).  Confirmation of a 125-bp product was conducted using 1% agarose gel 
electrophoresis, and libraries were sequenced using Illumina 50-bp single end sequencing 
at the Harvard Medical School Biopolymer Facility.  Data was analyzed by sorting based 
on barcodes using a custom script in Java Eclipse, then using CLC Genomics Workbench 
v. 7.2 for subsequent bioinformatics.  Reads were trimmed to remove adapter and 
transposon sequences and aligned to the B. pseudomallei 1026b genome using the default 
settings in the RNA-seq function in CLC.  Reads that mapped to multiple locations were 
discarded.  The resultant reads were counted and normalized to the reads per kilobase of 
transcript per million reads mapped (RPKM) and compared across sample sites.  
Significance was assessed using the On Proportions function of CLC using the Kals’s test 
option and the Bonferroni multiple testing correction was applied to the comparisons.  
Initially, fold change measurements of less than -3 (reduced in the mouse samples 
compared to the input pool) with a Bonferroni-adjusted p-value of less than 0.05 were 
considered significant. 
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2.8 Early Dissemination Studies 
	
Early dissemination studies were conducted using the B. pseudomallei Tn-Seq library 
strain to infect groups of three animals by IMIT as described above, euthanizing groups 
at 6, 12 and 24 hrs post infection.  Lung, liver and spleen from individual animals were 
collected at necropsy, homogenized and serial diluted for bacterial enumeration as 
described [77].   
 
2.9 Type 6 Secretion System Mutagenesis 
To generate a Type 6 Secretion System cluster 5 (T6SS5) mutant in B. pseudomallei, an 
internal in-frame 1,437 bp region of the tssC-5 gene was deleted.  Briefly, flanking 
fragments in the 5’ and 3’ region of the tssC-5 gene were amplified with the following 
primer sets: 5-tssC-F, GAAGAATTCGCGTAGAACAGCAGCAGCAGCAGCCCCGC; 
5-tssC-R, GTCAAGCTTCGGGGATTGCAGGTGTTCGCCTTCCATGGTC; 3-tssC-F, 
GTCAAGCTTTCGCTCGTCGGCAAGCTCGAAAAGCGCTAGG; 3-tssC-R, 
GGCGGTACCTTGCGCGAAGCCGCCCGCGAG.  The amplified 5’ tssC-5 fragment 
was cloned into pSK as an EcoRI/HindIII fragment to yield pSK-5’tssC.  The amplified 
3’ tssC-5 fragment was cloned into pSK-5’tssC as a HindIII/KpnI fragment to yield pSK-
ΔtssC-5.  The assembled fragment was cloned into pKAS46 as an EcoRI/KpnI fragment 
to yield pKAS46-ΔtssC-5 and conjugated with the parent B. pseudomallei strain DD503.  
Finally, the bioluminescent strain JW280 ΔtssC-5 was constructed by conjugation of 
DD503 ΔtssC-5 with S17-1/pKAS46-araPtolClux, as described previously [64].   
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2.10 Virulence Assessment of a T6SS5 Mutant in Respiratory Melioidosis 
	
Animal studies were conducted to compare the virulence of JW280 and the JW280 
ΔtssC-5 mutant by IMIT infection, as described above.  Groups of five animals were 
euthanized at moribund end point defined as loss of righting reflex.  Mice were 
necropsied and lung, liver and spleen were isolated and imaged for bioluminescence in 
24-well black plates.  Correlations between bioluminescent signal and colony forming 
units (CFU) have been previously defined [78]. 
 
2.11 Competition Studies 
	
A gentamicin resistance cassette was amplified with flanking NotI restriction sites from 
the pGSV4 vector [78] with the primers Gm cass NotI(+) 
(GCGGCCGCAGATTTAAATTAATTAAGAGCTAGAATTGACATAAGCCTG) and 
Gm cass NotI(-) (GAAGCGGCCGCGGCGTTGTGACAATTTACCGAACAACTC).  
The Gm cassette was cloned into the pCR®-Blunt II-TOPO cloning vector (Invitrogen) 
and was then cloned into the pUC19-araPtolClux vector as a NotI/NotI fragment to yield 
pUC19-araPtolClux-Gm.  The araPtolClux-Gm fragment was cloned into pKAS46 to 
generate the pKAS46-araPtolClux-Gm and was transformed into S17-1 cells to generate 
the S17-1/pKAS46-araPtolClux-Gm strain.  This strain was conjugated with the B. 
pseudomallei parent strain DD503, capsule polysaccharide mutant (JW270), Type 3 
Secretion System translocation-deficient mutant (DD503 ΔsctUBp3) and Type 6 Secretion 
System mutant (DD503 ΔtssC-5) to generate MGBP001, MGBP001 Δwcb, MGBP001 
ΔsctUBp3, and MGBP001 ΔtssC-5, respectively, by allelic exchange as previously 
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described [19].  Competition studies were conducted by challenging animals by IMIT 
with ~104.0 CFU of a 1:1 mixture of non-luminescent B. pseudomallei DD503 plus one of 
the four luminescent, gentamicin-resistant MGBP001 strains.  The study was completed 
at 67 hrs post infection at which point lung, liver and spleen were isolated and 
homogenized.  Homogenates were plated in replicate on both LB and LB-Gm plates for 
bacterial enumeration and competitive index calculations.   
 
2.12 Infection of cultured cells  
	
J774A.1 and RAW264.7 cultured macrophages were maintained in DMEM 
supplemented with 10% fetal bovine serum and grown at 37° C with 5% CO2.  For 
growth kinetics studies, J774A.1 macrophages were seeded at 7.5 x 104 cells per well 
(100 µl) in black, solid bottom 96-well plates 1 day prior to infection.  Bioluminescent B. 
pseudomallei strains were grown as previously indicated.  Bacterial concentrations were 
estimated from OD600 readings and bacterial suspensions were diluted in PBS to desired 
concentrations.  Cells were infected with 5 µl of the diluted bacterial suspension. 
Infections with individual strains were done in triplicate at multiplicities of infection 
(MOI) ranging from 2.4 to 3.6 for the parental strain and 6.0 to 2.2 for mutant strains.  
Sample wells were treated with gentamicin (20 µg/ml final concentration) 1 hr post 
infection for the duration of the experiment.  For siRNA knockdown studies, RAW264.7 
macrophages were infected at an MOI of 10. Bioluminescence measurements were taken 
every 10 minutes for a total of 14 h post infection using the IVIS Spectrum Imaging 
System (Caliper Sciences).
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2.13 Cell transfection 
	
HEK293 cells were maintained in DMEM supplemented with 10% fetal bovine serum 
and grown at 37°C with 5% CO2.  Cells were seeded at 6 x 104 cells per well (1 ml) on 
glass coverslips in clear 24-well plates 1 day prior to infection.  600 ng of p3XFLAG-
bopA was transfected into the cells for 24 hrs using PEI as per manufacturer’s 
instructions.  For siRNA transfection, 20 µl of 0.165 µM Silencer siRNA targeting 
TRAPPC8 diluted in Opti-MEM was mixed with 10 µl of Lipofectamine RNAi 
Max/Opti-MEM as per manufacturer’s instruction. 30 µl of siRNA-Lipofectamine 
complex was added to each well of a black, solid bottom 96-well plate, incubated for 10 
min and 1 x 104 RAW264.7 macrophages suspended in 80 µL of DMEM + 10% fetal 
bovine serum were added to the wells.  Cells were incubated for 48 hrs at 37°C with 5% 
CO2 before infection.  Cells were infected as previously mentioned. 
 
2.15 Immunofluorescent staining and confocal microscopy 
	
For confocal microscopy, cells were fixed to coverslips with 2.5% paraformaldehyde for 
15 min and washed 3 times following incubation. An anti-3XFLAG antibody diluted 
1:200 in PBS was used for BopA-3XFLAG detection and cells were incubated in 17 µl of 
the diluted antibody.  Unbound antibody was washed 3 times with PBS and 17 µl of 
Alexa Fluor 488 antibody diluted 1:4000 was used to detect the primary antibody.  
Unbound antibody was washed 3 times with PBS and 17 µl of Phalloidin-
Tetramethylrhodamine diluted 1:4000 was used for F-actin staining.  Unbound antibody 
was washed 3 times with PBS and glass cover slips were mounted on glass slides using 
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Prolong Gold mounting media with DAPI.  For vacuolar membrane staining, RAW264.7 
macrophages were incubated with the lipophilic styryl dye FM4-64FX for 1 hr prior to 
infection as per manufacturer’s instructions.  Unbound FM4-64FX dye was washed 3 
times with PBS and cell infections and vacuole isolation were conducted as previously 
described.  For BopA localization studies, sample plates were placed on ice to stop the 
progression of infection at 2 hrs post infection.  Extracellular bacteria were labeled with 
mouse anti-BpMAb2 primary antibody and detection of the primary antibody was done 
with an AMCA donkey anti-mouse secondary antibody.  Cells were then fixed with 2.5% 
paraformaldehyde for 15 minutes.  Loading of anti-BpMAb2 primary antibody into the 
cytoplasm of RAW264.7 cells for detection of cytoplasmic bacteria was accomplished by 
selective permeabilization of the cells’ plasma membrane with the mild detergent 
digitonin, at a concentration of 10 ng/mL.  And detection of the primary antibody was 
done with donkey anti-mouse Alexa® 547-Tetramethylrhodamine.  Samples were 
analyzed with the Zeiss LSM Duo-LSM5 Confocal Microscope.  
 
2.16 Statistical analyses 
	
Student T-test, one-way ANOVA followed by Tukey’s Multiple Comparison test, two-
way ANOVA followed by the Bonferroni post-test, student T-test, Log-rank survival 
analyses (Mantel-Cox test and Gehan-Breslow-Wilcoxon test) were conducted in 
GraphPad Prism.  Probit analysis (Finney Method, StatPlus 2009 Professional) was used 
to calculate LD50 +/- standard error, which was subsequently subjected to Student T-test 
analysis to investigate significant differences of LD50 values of different B. pseudomallei 
strains.
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Table 1.  Strains used in this study. 
Strain Description Reference 
S17-1  E. coli conjugation strain, λpir [81] 
S17-1/pKAS46-
araPtolClux 
Bioluminescence allelic exchange construct [73] 
S17-1/pKAS46-
ΔtssC-5 
T6SS5 mutant allelic exchange construct This study 
DD503 B. pseudomallei 1026b derivative, PmR SmR KmS 
GmS, lacking AmrAB-OprA efflux pump 
[82] 
DD503 ΔtssC-5 T6SS5 mutant This study 
DD503 ΔsctUBp3 T3SS3 mutant [19] 
JW270 DD503 Δwcb capsule mutant [60] 
JW280 DD503::PtolC-luxCDABE [73] 
JW280 ΔbopA Bioluminescent bopA mutant This study 
JW280 ΔbopC Bioluminescent bopC mutant This study 
JW280 ΔbopE Bioluminescent bopE mutant This study 
JW280 ΔbapA Bioluminescent bapA mutant This study 
JW280 ΔbapC Bioluminescent bapC mutant This study 
JW280 ΔtssC-5 Bioluminescent T6SS5 mutant This study 
MGBP001 DD503::PtolC-luxCDABE-Gm This study 
MGBP001 ΔtssC-5 Bioluminescent, GmR T6SS5 mutant This study 
MGBP001 ΔsctUBp3 Bioluminescent, GmR T3SS3 mutant This study 
MGBP001 Δwcb Bioluminescent, GmR capsule mutant This study 
MGBP002  Green Fluorescent Protein expression, JW270 This study 
MGBP002 ΔsctUBp3 Green Fluorescent Protein expression, JW270 This study 
MGBP002 ΔbopA Green Fluorescent Protein expression, JW270 This study 
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Table 2.  Plasmids used in this study. 
 
Plasmid   
pBTK30 Vector containing Himar1 C9 transposase [83] 
pSAM-Bt Tn-seq vector for use in Bacteroides 
thetaiotaomicron 
[84] 
pSAM-DYH pSAM_Bt with the transposase from pBTK30 
inserted as a BamHI fragment to replace the 
native transposase and promoter 
[85] 
pEXKm5 Gene replacement vector for Burkholderia 
species 
[86] 
pSAM-DKm Tn-seq vector This study 
pKAS46 Allelic exchange vector providing KmR and SmS 
in DD503 genetic background 
[87] 





Topoisomerase-conjugated cloning vector Invitrogen 




TYPE 3 SECRETION SYSTEM CLUSTER 3 IS A CRITICAL VIRULENCE 




Naturally acquired melioidosis typically involves percutaneous inoculation or 
inhalation of pathogen by susceptible hosts, with many risk factors such as diabetes and 
alcoholism leading to the presentation of clinical melioidosis [88].  Under exceptional 
conditions, such as natural disasters, otherwise healthy individuals are also susceptible to 
melioidosis [89-92], suggesting that dose and route of inoculation are key elements to 
determining whether or not a healthy individual acquires disease.  The ability of B. 
pseudomallei to establish a lethal respiratory disease combined with its inherent 
resistance to numerous classes of antibiotics and the lack of licensed vaccines against the 
bacterium, highlights the importance of characterizing respiratory melioidosis for the 
purposes of biodefense. 
Respiratory melioidosis has been well studied in surrogate animal models for both 
basic science investigations as well as therapeutic studies.  B. pseudomallei has a 
significant lung tropism, irrespective of the route of acquisition [88], and is able to spread 
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to other tissues to cause a lethal systemic disease.  Bioluminescent B. pseudomallei 
strains have been generated which allow for the temporal assessment of disease 
progression in individual animals using optical diagnostic imaging.  In the first of such 
studies, a non-lethal intranasal challenge revealed that B. pseudomallei prominently 
colonizes the upper respiratory tract (URT) of mice, leading to a rapid development of 
meningitis within 24 hours, likely resulting from spread to the olfactory bulbs via 
olfactory nerve endings [93].  Interestingly, the symptoms of a prominent URT 
colonization (rhinitis, sinusitis, tonsillitis, laryngitis, and otitis media) have not been 
described as common presentations of melioidosis [94, 95], suggesting that URT 
infections do not play a prominent role in humans as that observed in murine models.  
Indeed, a large clinical sampling study of throat swabs revealed no carriage of B. 
pseudomallei in healthy volunteers, while melioidosis patients had culturable B. 
pseudomallei from the throat in 36.1% of cases [96], less than the presentation rate of 
pneumonia at 50% [97].  Additionally, paired analyses of throat and sputum carriage 
from the same patient demonstrated that B. pseudomallei culture from the throat is 
underrepresented relative to sputum culture, suggesting that presence of B. pseudomallei 
in the lung is not a direct result of a descending infection from a colonized throat [96].  
These clinical trends, combined with the relatively rare presentation of meningitis at an 
incident rate of 4-5% [97, 98], suggest that murine models in which B. pseudomallei is 
delivered intranasally over-represent the incidence of URT disease and central nervous 
system (CNS) involvement in studies of respiratory melioidosis.  Significant URT 
colonization was also observed by diagnostic optical imaging in a lethal intranasal murine 
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model of respiratory melioidosis [73], suggesting that the URT colonization phenotype is 
not specific to sub-acute disease. 
The role of murine URT colonization on studies of respiratory melioidosis is 
poorly understood though may have a significant impact on both basic and translational 
studies.  A recent study investigating an intratracheal instillation of B. pseudomallei 
directly into the lungs successfully demonstrated that avoidance of initial URT 
colonization could limit both CNS involvement and late stage URT colonization [99].  
This finding is consistent with other studies demonstrating the mechanism by which 
melioidosis-associated meningitis arises from spread to the brain from the nasal cavity 
within 24 hours using both olfactory and trigeminal nerves [100].  Because intratracheal 
delivery is capable of avoiding such URT and CNS involvement, an unanswered question 
is what impact these cephalic disease presentations have on disease outcome of 
pneumonic and systemic disease.  We have developed a non-surgical approach to deliver 
bacteria directly into the lung as a novel instillation strategy termed intubation-mediated 
intratracheal (IMIT) inoculation, which we have validated to provide >98% efficiency in 
pulmonary delivery [75], and we therefore used this highly accurate lung inoculation 
approach to study the impact of lung-specific melioidosis on dissemination and disease 
outcome.  Additionally, we investigated whether lung-specific administration of capsular 
polysaccharide and type 3 secretion mutants exhibit modified courses of disease relative 
to previous characterization in other respiratory murine models.  Using a combination of 
optical diagnostic imaging, targeted lung-specific delivery of B. pseudomallei, and 
previously characterized virulence system mutants, we demonstrate that the presence or 
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absence of URT infection in murine models exhibits significant disease outcome 




3.2.1 Lung-specific delivery of Burkholderia pseudomallei impacts disease 
progression 
	
Opportunistic URT colonization by B. pseudomallei is associated with high rates 
of meningitis in murine respiratory models [93, 101], and avoidance of bacterial 
deposition on the nasal mucosa by intratracheal instillation is associated with reduced 
CNS involvement [99].  We decided to investigate whether the URT colonization typical 
of current respiratory melioidosis models impacts the moribund disease presentation.  To 
investigate this, we employed a non-surgical approach that would facilitate direct 
instillation of bacteria directly into the lungs of mice with >98% efficacy [75], termed 
intubation-mediated intratracheal (IMIT) delivery [74]. Albino C57BL/6J mice were used 
as a model system in these studies given the myriad of transgenic tools available in the 
C57BL/6J background, and the importance of coat color in optimizing detection of 
bioluminescent bacterial pathogens [76].  Thus, albino C57BL/6J mice were infected 
with 104 CFU of luminescent B. pseudomallei strain, JW280, using either intranasal or 
IMIT delivery and monitored twice daily by optical diagnostic imaging.  While challenge 
with 104 CFU by both routes of inoculation resulted in moribund disease over a similar 
time frame, the foci of disease in moribund animals was dramatically different (Figure 3). 
As observed in our previous work with a BALB/c model [73], C57BL/6J mice infected 
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intranasally developed a significant URT infection with a reduced bioluminescent signal 
associated with the thoracic cavity/lung (Figure 3).  Interestingly, mice infected in a lung-
specific manner by IMIT developed a pulmonary infection earlier than by intranasal 
delivery of the same inoculum, consistent with estimates that 10% of an intranasal 
inoculum is delivered to the lung for other respiratory pathogens [102].  Importantly, the 
early involvement of the lung in the IMIT model led to more severe pneumonic disease 
than that observed in the intranasal model, with subsequent systemic spread not 
previously observed in the intranasal model.  This suggests that mice are capable of 
sustaining an advanced systemic disease than previously thought possible in the 
intranasal model, and therefore that URT colonization by B. pseudomallei directly 
contributes to the host morbidity of the intranasal model.   These data indicate that 
avoiding initial deposition of bacteria in the upper respiratory mucosa represents an 
important modification for studying the development of pneumonia and subsequent 
systemic spread. 
 
3.2.2 Respiratory melioidosis models exhibit similar disease kinetics 
	
We decided to examine whether the kinetics of respiratory disease vary as a 
function of the method of delivery in order to investigate whether the involvement of 
different foci of infection impacts the median time to death (MTTD).  Mice were infected 
by either intranasal or IMIT instillation and both respiratory disease models were able to 
establish an acute course of disease in C57BL/6J mice with a typical MTTD of ~4 days 
(Figure 4).  We observed typical dose response disease susceptibility in the intranasal 
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model with a transition from 100% survivors to 100% fatality over a 32-fold dose range 
(Figure 4A).  Interestingly, we observed a much sharper dose transition in host 
susceptibility to disease in the IMIT-infected groups, which occurred over a single ten-
fold dose range (Figure 4B).  We calculated the LD50 of the intranasal C57BL/6J model 
to be 12.1 ± 2.4x103 CFU, while the IMIT model significantly lowered the LD50 to 5.4 ± 
2.0x103 CFU (P = 0.04).  Thus, targeting of B. pseudomallei directly into the lungs of 
mice resulted in a lowering of the LD50 and resolved host susceptibility into a more 
discrete dose range transition from susceptibility to clearance of pathogen.  Importantly, 
the small 2.2 fold change in the LD50 and similar MTTD at equivalent doses suggest that 
the ultimate course of disease takes place over a similar time frame, regardless of the 
method of inoculation, but that the disease presentation is dramatically altered dependent 
on whether B. pseudomallei spreads specifically from the lung, or whether initial 
inoculation prominently colonizes the URT.  We conclude that intranasal and IMIT 
respiratory infections therefore cause very different morbidity in the host as a result of 
either primarily URT or systemic endpoints, respectively. 
To further investigate the role of URT colonization on disease endpoints, we 
subsequently investigated the bacterial burdens of tissues isolated from moribund mice to 
further characterize differences in bacterial dissemination.  Tissues were necropsied from 
moribund mice infected with ~LD100 doses of JW280 by either the intranasal or IMIT 
routes of infection, and we compared the tissue burdens of moribund animals for the 
lung, liver, spleen, BAL and blood of mice infected with (i.n.) or without (IMIT) 
involvement of the URT.  Consistent with the findings of Figure 3, we found that IMIT 
delivery of B. pseudomallei facilities significant disease in all monitored tissues, both at 
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the primary site of infection in the lung, as well as in the disseminated infection of the 
liver and spleen (Figure 5).  Further, we observe a >3 log CFU difference of bacterial 
dissemination through the blood, indicating that moribund mice exhibit a greater degree 
of septicemia in the IMIT model relative to the i.n. model.  Consistent with in vivo 
diagnostic imaging, bacterial tissue burden analysis reveals that B. pseudomallei 
infections involving prominent URT colonization result in host morbidity associated with 
reduced disease maturation in core body sites, suggesting that the host morbidity of the 
i.n. model is directly influenced by the bacterial colonization of the nasal cavity. 
 
3.2.3 Sex difference influence host susceptibility to lung-specific melioidosis 
	
Given a recent focus in the scientific community on understanding disease 
progression in both male and female model systems [103], we additionally performed 
survival analyses in male albino C57BL/6J mice to investigate whether sex differences 
impact susceptibility to lung-specific respiratory melioidosis.  Male disease progression 
closely mirrored that observed in the female models (Figure 4 and 6), where in both 
cases, the 100% minimally lethal dose was observed at 104.2 CFU by IMIT, with a 91 hr 
MTTD.  We calculated the LD50 for lung-specific melioidosis in male mice as 1.9 ± 
1.2x103 CFU, which was 2.9 fold reduced relative to the female LD50 (P = 0.25).  Thus, 
male mice are not significantly different in their susceptibility to respiratory melioidosis 
relative to female mice in the C57BL/6J IMIT model system.   
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3.2.4 Type 3 Secretion is more critical for respiratory melioidosis than capsule 
	
We observed that URT colonization impacts disease outcome in the murine 
respiratory melioidosis model, and we therefore hypothesized that URT colonization 
could impact our basic understanding of the role of virulence determinants in mediating 
B. pseudomallei pathogenesis.  Previous murine studies demonstrated that a capsule 
mutant LD50 is attenuated 101.8 fold in a respiratory melioidosis model [60], and that 
T3SS3 is also required for the full virulence in an equivalent dose challenge [104].  We 
therefore examined the response of albino C57BL/6J mice infected with increasing doses 
of either a luminescent capsular polysaccharide mutant (JW280 Δwcb) or a T3SS3 
mutant (JW280 ΔsctUBp3).  We found that a capsule mutant inoculated by IMIT was not 
significantly attenuated relative to the wild type strain, with a capsule mutant LD50 
calculated to be 104.57 CFU (6.8 fold attenuation, P = 0.60).  We observed a MTTD of 72 
hrs at an ~LD100 challenge (Figure 7A), which represents a faster course of disease than 
the ~LD100 dose of wild type at 91 hrs, albeit with a larger challenge dose.  Thus, the 
JW270 capsular polysaccharide mutant is not significantly attenuated in the lung-specific 
IMIT model, contrasting with our prior findings in the i.n. model.  In the IMIT model, the 
T3SS3 mutant had a calculated LD50 of 106.19 CFU, which represents a significant 
attenuation of 102.5 fold (P= 0.004).  The course of disease of the T3SS3 was observed to 
have a MTTD of 79 hr at the minimally lethal dose (Figure 7B), which like the capsule 
mutant strain was faster than the wild type MTTD, albeit with a larger challenge dose.  
Thus, in a lung-specific respiratory melioidosis model, T3SS3 is a critical virulence 
	 50	
determinant for B. pseudomallei in the lung, whereas the capsular polysaccharide appears 
to play a more minor role.   
 
3.2.5 Capsule and T3SS3 mutants are defective in spread from the lung 
	
We decided to further investigate whether abrogation of URT colonization in our 
lung-specific disease studies impacts the dissemination potential of the capsule and 
T3SS3 mutants.  We performed optical diagnostic imaging of ~LD100 infections of the 
wild type strain as well as both the capsule and T3SS3 mutants to characterize bacterial 
burdens at moribund disease.  We found that the wild type strain is capable of 
dissemination beyond the lung to colonize all sites of the body at high titer (Figure 8).  
The capsule and T3SS3 mutants developed significant bacterial pneumonia yet exhibited 
a spread deficiency with minimal bacterial burden outside of the lung (Figure 8).  We 
further characterized the dissemination defects of these mutants by enumerating bacteria 
from the lung, liver and spleen, from mice infected with minimally lethal doses of each 
strain.  We found that while all tested strains established bacterial pneumonia of 108-109 
CFU per tissue, the capsule and T3SS3 mutants exhibited significant dissemination 
defects to the liver and spleen in both tissues (Figure 9).  These data demonstrate that a 
capsule mutant exhibits reduced fitness to disseminate from the lung, consistent with the 
previously characterized role of capsular polysaccharide in mediating complement 
protection [59].  Thus, a capsule mutant is capable of producing a lethal pneumonia with 
a similar LD50 as wild type, yet without the wild type-ability to spread beyond this organ.  
In contrast, the T3SS3 virulence determinant exhibits significantly reduced fitness in the 
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lung by LD50 analysis, and this reduced fitness is also associated with a reduced 
dissemination potential to the liver and spleen.  Thus, both the capsule and T3SS3 
mutants are spread deficient when delivered specifically to the lung, highlighting a major 
difference between the current lung-specific respiratory melioidosis model versus our 
previous work with i.n. models.  This finding suggests that the differences in respiratory 
melioidosis models, with respect to URT involvement in dissemination and endpoint, 
dramatically influences our interpretation of basic science investigations of the role of B. 
pseudomallei virulence determinants. 
	
 3.2.6 T3SS3 mutant exhibits reduced fitness in lung over the course of disease 
	
We hypothesized that the reduced fitness characterized at moribund disease would 
similarly be associated with a reduced fitness throughout the course of disease.  We 
therefore performed optical imaging of mice infected at a ~LD100 dose of JW280, JW280 
Δwcb, or JW280 ΔsctUBp3 and quantified the in vivo bioluminescence until moribund 
endpoints were reached.  We identified an in vivo logarithmic increase in 
bioluminescence of all strains in the lung, but observed that the T3SS3 mutant exhibited 
reduced fitness relative to both wild type and capsule mutant strains (Figure 10).  The 
bioluminescence-doubling rate was calculated for all strains and we found non-significant 
differences of the doubling rates of the wild type and capsule mutant strains of 9.88 and 
9.24 hrs, respectively (One-way ANOVA/Tukey not significant).  However, the T3SS3 
mutant bioluminescence doubled at a significantly reduced rate of 13.64 hrs (P<0.001), 
suggesting that the T3SS3 mutant is less fit to grow in host niches and/or is subject to 
enhanced clearance by the host.  This finding is consistent with our study data, 
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highlighting T3SS3 as a critical virulence determinant for B. pseudomallei lung 





We have previously developed an optical diagnostic imaging model of intranasal 
respiratory melioidosis and observed that the URT of mice infected in this manner are 
subject to prominent infection [73].  URT colonization is associated with infection of the 
nasal-associated lymphoid tissue (NALT) as well as infection of the olfactory bulbs/CNS 
[93, 100].  As discussed above, descriptions of disease states associated with URT 
infections have not been described in human melioidosis, and paired analysis of culture 
sputum and throat swabs suggests that pneumonia gives rise to the presence of B. 
pseudomallei at the top of the respiratory tract rather than URT carriage seeding a 
primary infection which descends to the lung [96].  The over-representation of these 
symptoms in mice have led us, and others, to investigate alternatives to the standard 
approaches of inoculating mice with B. pseudomallei through the nares.  A recently 
developed intratracheal model of respiratory melioidosis succeeded in abrogating CNS 
infections, suggesting that URT colonization is directly responsible for the high levels of 
meningitis reported in the murine model [99, 105]. Our current studies focused on 
advancing these findings by identifying whether URT infection in the mouse impacts the 
overall course of disease and ask whether these impacts might influence both basic and 
translational studies of respiratory melioidosis. 
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Importantly, we found that inoculation of B. pseudomallei directly into the lung 
dramatically altered disease outcome, where we observed significant increases in both 
lung burden and septicemic spread not previously observed in intranasal inoculation 
studies.  Our survival analysis of intranasal and IMIT-infected mice revealed that both 
routes of infection supported a disease process with very similar timing of inoculation to 
moribund endpoint; however, the major difference between the models was the difference 
in which host tissues supported the dominant site(s) of infection.  IMIT also lowered the 
LD50 relative to the i.n. model and provided an earlier development of pneumonia which 
progressed to advanced systemic disease.  Intranasal infection exhibits a clear bias to 
nasal cavity colonization, and conversely the IMIT model achieves systemic disease at 
moribund endpoints.  This difference in infection site at moribund disease strongly 
suggests that the causation of moribund presentation is very different in these models, 
with IMIT providing systemic, general organ failure disease, while the moribund disease 
of the intranasal model is very directly related to the bacterial burden in the nasal cavity.  
Pathological analysis of the URT of mice infected by the i.n. route revealed significant 
blockage by inflammatory cell debris in the nasal turbinates [105], thus the severe 
pathology/rhinitis of the intranasal model likely promotes moribund disease.  Both IMIT 
and i.n. models have moribund disease symptoms which include labored breathing of 
mice, and given that mice are obligate nasal breathers, we hypothesize that nasal cavity 
occlusion in the intranasal model drives moribund endpoints while the labored breathing 
of the IMIT model may reflect greater lung pathology, as the IMIT model supported >1 
log more bacteria per lung than the i.n. model.  Future studies will be required to 
investigate whether the aerosol model, which would also involve the nasal mucosa as a 
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primary site of infection, is similarly subjected to preferential colonization of the URT 
over systemic spread. 
The IMIT inoculation method we developed is distinct from other non-invasive 
intratracheal instillation methods, including those used previously for B. pseudomallei 
instillation [99].  IMIT inoculation is a two-step process in which mouse intubation is 
followed by instillation of bacteria via a long blunt needle, and the approach facilitates an 
intermediate confirmation of correct catheter placement into the trachea (rather than the 
esophagus), and is therefore not prone to user error associated with unintentional mis-
inoculation of the GI tract [106].  IMIT inoculation also benefits from being a non-
invasive approach, which avoids overt deposition of bacteria into the blood stream, which 
could occur as a result of surgical intratracheal inoculation. 
This study incorporated use of albino C57BL/6J mice as a novel host model 
system in which to study respiratory melioidosis.  A vast array of murine transgenic lines 
are available to the research community, the majority of which are available in the 
C57BL/6J background, which have been, and will continue to be important tools in 
melioidosis studies.  C57BL/6 mice are commonly referred to as representing a chronic 
model of melioidosis, however both in the intranasal and IMIT infection studies we found 
that C57BL/6J mice develop an acute disease with a MTTD of 3-4 days.  While 
C57BL/6J mice do appear to have a higher resistance to respiratory melioidosis with 
intranasal LD50 values 1-3 logs higher than their BALB/c counterparts [107], we 
conclude that C57BL/6J mice successfully model an acute respiratory disease 
presentation.  We further made use of tyrosinase-negative mice, which have albino coats 
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and therefore offer greater sensitivity over black-coated mice to detect bioluminescent 
bacteria, which is necessary to monitor the early stages of disease progression in vivo. 
We hypothesized that the improved ability to study disease maturation of 
respiratory melioidosis in the absence of URT colonization might influence the role of 
virulence determinants in mediating B. pseudomallei pathogenesis.  Given our prior 
interest in studying the role of capsular polysaccharide in mediating B. pseudomallei 
dissemination from the lung, we investigated the role of a capsule mutant using IMIT 
inoculation.  Unlike our previous work which identified an attenuation of the Δwcb 
capsule mutant of 101.8-102.3 fold in intranasal models [60, 73], we found a non-
significant attenuation of just 6.8 fold (100.8) in the IMIT model, suggesting that the 
capsular polysaccharide is not absolutely critical for the initial stages of lung 
colonization.  From our growing understanding of the difference between i.n. and IMIT 
models, we conclude that the capsule mutant is attenuated in its ability to colonize the 
nasal mucosa as the contributor to its greater attenuation in the i.n. model, and conversely 
that capsular polysaccharide is not as critical for disease in the lung.  More importantly, 
we further characterized whether the capsule mutant is required for dissemination beyond 
the lung.  In our previous studies, we had found that there was no significant defect in 
dissemination of the capsular polysaccharide mutant when studied at the minimally lethal 
dose in the murine intranasal model [60].  This previous observation had not been 
anticipated given the previous demonstration that capsular polysaccharide is required to 
resist opsonization by host complement likely during dissemination through the blood 
stream [59], and further that capsule is a critical virulence determinant in systemic 
disease models of both the hamster and mouse with an attenuation of ~105 fold [61, 62].  
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Importantly, our current studies provide a modified understanding of the role of capsular 
polysaccharide in mediating dissemination beyond the lung, as we now observe that a 
capsule mutant is defective in lung-specific dissemination both optical diagnostic 
imaging as well as tissue burden analysis.  We retrospectively interpret our previous 
studies to suggest that capsular polysaccharide mutants are attenuated for colonization of 
the URT mucosa, and that a capsule mutant is competent to disseminate from the URT to 
the liver and spleen at wild type levels, possibly involving the NALT and lymphatic 
system, as has been proposed for B. pseudomallei spread by others [93].  Only through 
studying the capsule mutant in a lung-specific model system have we identified a 
dissemination defect for this mutant, consistent with a dominant role for capsular 
polysaccharide as a defense to innate immunity, thereby facilitating disseminated disease.  
Thus, the study of the role of virulence determinants in respiratory melioidosis may give 
different phenotypes dependent on whether disease is mediated by URT infection (i.n.) or 
systemic disease progression (IMIT).   
Type 3 Secretion has been characterized as an important B. pseudomallei 
virulence determinant in hamster and murine systemic disease models as well as a murine 
intranasal model system [19, 104].  B. pseudomallei possesses three T3SS clusters in its 
genome [45, 46, 108], of which only cluster 3 was found to be important for mammalian 
virulence, with a calculated attenuation of 102.8 fold in a systemic hamster intraperitoneal 
model [19].  Given that our IMIT model revealed a reduced importance for the role of 
capsule in B. pseudomallei pulmonary pathogenesis, we investigated whether T3SS3 is 
an important B. pseudomallei virulence determinant in the lung, or whether it too is 
required preferentially for systemic infection rather than initial lung colonization.  
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Interestingly, we found that a T3SS3 translocation defective mutant was attenuated 102.5 
fold, similar to the 102.8 fold attenuation reported in a systemic model.  Thus, unlike the 
capsule mutant, which is critical for systemic, but not respiratory, disease, T3SS3 is 
required ubiquitously for both systemic and respiratory disease.  It is understood that a 
critical phenotype associated with the T3SS3 locus is mediating the ability of B. 
pseudomallei to rapidly escape from the phagosome of professional phagocytes [38, 109].  
Thus, T3SS3 mutants exhibit growth defects in intracellular niches associated with 
delayed vacuolar escape, suggesting that the decreased fitness, which we have observed 
for the T3SS3 mutant in the lung, is associated with reduced fitness in the intracellular 
environment.  Our data suggests that B. pseudomallei inhabits intracellular niches, not 
only in the lung, but also in other tissues, which might explain why a similar degree of 
attenuation is observed for the T3SS3 mutant in both systemic and respiratory disease 
models.  We are therefore interested in identifying how specific effector proteins 
delivered by the T3SS3 apparatus participate in mediating vacuolar escape and increase 
the fitness of B. pseudomallei in the lung. 
In summary, we have demonstrated that respiratory melioidosis in the murine 
model may be associated with severe upper respiratory inflammation, which directly 
drives host morbidity.  We have further demonstrated that simple approaches facilitating 
a lung-specific disease progression allow for abrogation of URT infection, and therefore 
allow mice to act as much better surrogates for human melioidosis, minimizing the role 
of URT-based morbidity and CNS involvement.  This approach has profound impact both 
in translational studies as well as basic science investigations.  In the case of the former, 
full disease progression in the mouse will allow an investigation of the efficacy of pre- 
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and post-exposure prophylaxis to protect against an advanced septicemic disease state.  
With regards to basic science investigations, we have successfully used the IMIT model 
to meet prediction of the role of capsular polysaccharide in facilitating dissemination of 
B. pseudomallei from the lung, whereas our former intranasal model system did not allow 
us to draw these predicted conclusions.  The IMIT model has also revealed a critical role 





Figure 3. In vivo optical diagnostic imaging of respiratory melioidosis. 
Female albino C57BL/6J mice were challenged with 104 CFU of luminescent B. 
pseudomallei strain JW280 by either the intranasal (Top panel) or IMIT (Bottom panel) 
routes of infection.  Mice were imaged twice-daily beginning at 18 h post infection.  
Images were uniformly adjusted to a range of 2.5x103 to 3x104 p/s/cm2/sr on a 
logarithmic scale.  A representative panel of images beginning 53 hr post infection is 
presented for both infection routes, where the last image of each panel represents the 





Figure 4.  Host response to lung-specific delivery of Burkholderia pseudomallei.   
Groups of 5 female albino C57BL/6J mice were challenged with increasing doses of 
luminescent B. pseudomallei strain JW280 by either the intranasal (A) or IMIT (B) routes 
of infection.  Mice were monitored for 14 days (336 hr) for disease progression and 
euthanized at the onset of moribund disease presentation.  Survival curves are used to 
present the dose-dependent response of the host to increasing bacterial challenges. The 





Figure 5.  Bacterial enumeration at moribund disease for respiratory melioidosis 
models.  Groups of 5 female albino C57BL/6J mice were infected by either the i.n. (105.1 
CFU) or IMIT (104.6 CFU) routes of infection and euthanized at moribund disease 
endpoints.  Bacteria were enumerated from tissues homogenized in 1 ml PBS, from a 1 
ml PBS BAL collection, or from cardiac-drawn blood.  Bacterial burden was calculated 
as CFU/tissue (lung, liver, and spleen) or bacteria per ml of body fluid (BAL and blood).  
Significant differences between log transformed data were evaluated by 2-way ANOVA 






Figure 6.  Male host response to lung-specific delivery of Burkholderia pseudomallei.  
Groups of 3 male albino C57BL/6J mice were challenged with increasing doses of 
luminescent B. pseudomallei strain JW280 by IMIT infection.  Mice were monitored for 
14 days (336 hr) for disease progression and euthanized at the onset of moribund disease 
presentation.  Survival curves are used to present the dose-dependent response of the host 
to increasing bacterial challenges.  The MTTD was calculated for groups with ≥50% 




Figure 7.  Host response to capsule and T3SS3 mutants of Burkholderia 
pseudomallei.  Groups of 5 female albino C57BL/6J mice were challenged by the IMIT 
route of infection with increasing doses of either Δwcb capsule mutant (A) or ΔsctUBp3 
T3SS3 mutant (B) in the luminescent B. pseudomallei strain JW280 background.  Mice 
were monitored for 14 days (336 hr) for disease progression and euthanized at the onset 
of moribund disease presentation.  Survival curves are used to present the dose-dependent 
response of the host to increasing bacterial challenges of B. pseudomallei mutants. The 





Figure 8.  Detection of dissemination of Burkholderia pseudomallei mutants by 
optical imaging.  Groups of 5 female albino C57BL/6J mice were challenged by the 
IMIT route of infection with either wild type luminescent B. pseudomallei strain JW280, 
the Δwcb capsule mutant, or the ΔsctUBp3 T3SS3 mutant.  Representative images of 
disease endpoints are presented, with uniform image settings adjusted to a range of 





Figure 9.  Bacterial enumeration of Burkholderia pseudomallei mutants in moribund 
respiratory disease.  Groups of 5 female albino C57BL/6J mice were infected with wild 
type JW280 (104.2 CFU), Δwcb capsule mutant (106.0 CFU), or ΔsctUBp3 T3SS3 mutant 
(106.5 CFU), and euthanized at moribund disease endpoints.  Bacteria were enumerated 
from tissues ex vivo by optical imaging (left Y-axis: cps/tissue) with presentation of the 
estimated tissue CFU burdens based on calculated tissue-specific cps:CFU correlation 
(right Y-axis: CFU/tissue est.) for lung (A), liver (B) and spleen (C).  The 95% LOD was 
calculated as a technical background luminescence and indicated as a dotted horizontal 
line.  Data points below the 95% LOD were set to the 95% LOD value.  Significant 
differences (1-way ANOVA with Tukey posttest) between log-transformed data sets are 




Figure 10.  Detection of pulmonary growth rates of Burkholderia pseudomallei 
mutants in vivo.  Groups of 5 female albino C57BL/6J mice were infected with wild type 
JW280 (104.2 CFU), Δwcb capsule mutant (106.0 CFU), or ΔsctUBp3 T3SS3 mutant (106.5 
CFU), and monitored by optical diagnostic imaging once to twice daily.  ROIs from the 
dorsally-imaged thoracic cavity were plotted as a function of infection time for each 
mutant.  The 95% LOD was calculated for the background luminescence of uninfected 
mice and indicated as a dotted horizontal line.  The calculated doubling rate of 
bioluminescent signal of each strain is indicated.
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CHAPTER IV 
COMPREHENSIVE IDENTIFICATION OF VIRULENCE FACTORS REQUIRED 




Respiratory melioidosis is a disease presentation of high relevance to both 
naturally occurring and biodefense-related studies.  Both our laboratory and others have 
previously shown that the nasal cavity represents the predominant site of B. pseudomallei 
colonization in intranasally inoculated mice [73, 93], whereas direct lung instillation of 
bacteria can abrogate nasal cavity colonization and the associated central nervous system 
involvement [78, 99].  We have further characterized that lung-specific instillation of B. 
pseudomallei results in a shift of moribund endpoint from a predominant nasal cavity 
infection in the intranasal model to greater bacterial proliferation in the lung and 
disseminated spread [78], more closely resembling descriptions of human melioidosis. 
Furthermore, the intubation-mediated intratracheal (IMIT) inoculation method facilitated 
the discovery of a spread-deficiency phenotype for a capsular polysaccharide mutant 
from the lung [78], which had not been discovered in mice succumbing to nasal cavity 
colonization [73], and yet meets the predicted role for capsule in mediating 
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protection from complement during dissemination [59].  Thus, the IMIT lung-specific 
melioidosis model has begun to provide unique insights into the roles of B. pseudomallei 
virulence determinants that have not been identified in other respiratory melioidosis 
models.   
We sought to identify additional B. pseudomallei virulence determinants by 
combining our IMIT mouse model of lung-specific instillation with transposon 
mutagenesis.  Tn-seq is a powerful tool used to identify genes required for an organism’s 
fitness in a selective environment by combining saturation mutagenesis and Next 
Generation Sequencing [110].  Recent Tn-seq studies identified essential genes required 
to support in vitro growth for the Burkholderia pseudomallei K96243 strain [33] and the 
closely related Burkholderia thailandensis E264 strain [111, 112].  These studies 
identified potential antimicrobial drug targets in key constituents of metabolic pathways, 
cell structure and genes required for nucleotide and amino acid synthesis, and further 
estimated that ~8% of the Burkholderia genome represent essential genes [33, 111]. 
Importantly, Tn-seq has not been previously used to identify B. pseudomallei genes 
required to support growth in the selective pressure of mammalian host tissues.  In the 
present study, we investigated the potential of Tn-seq to identify virulence determinants 
required by B. pseudomallei to colonize mammalian lungs in a mouse model of 
respiratory melioidosis as well as to disseminate to the liver and spleen.  These studies 
take advantage of our IMIT respiratory melioidosis model to non-invasively target 
delivery of a Tn-seq library directly into the lungs of mice to specifically identify genes 
supporting pulmonary disease in the absence of potential interplay between upper and 




4.2.1 Lung-specific mouse infection with the Tn-Seq insertion library 
	
We sought to identify virulence determinants required by B. pseudomallei to 
cause disease specifically in the lung, as well as subsequent disseminated spread to the 
liver and spleen.  Accordingly, we generated a transposon insertion library composed of 
20,000 insertion mutants in the genome of the B. pseudomallei luminescent strain JW280, 
a derivative of the 1026b clinical strain.  To select against transposon-inactivated genes 
required for lung colonization and systemic spread in vivo, we challenged groups of three 
C57BL/6J albino female mice with 104.74 CFU of a transposon insertion library.  This 
inoculum was within 10 median lethal doses (LD50) of the JW280 strain [78], and 
achieved approximately 4x coverage of the genome and 4x mutant strain representation 
in the challenge inoculum.  We monitored the growth rate of the mutant library by 
bioluminescence starting at 19 hours post infection and observed that in the lungs, the 
library pool exhibited logarithmic growth at a rate consistent with our previously 
observed JW280 parent strain growth rate [78] (Figure 11A).  By 66 hours post infection, 
all animals had reached moribund stage, characterized by acute respiratory infection and 
systemic spread (Figure 11B) and at this point all animals were euthanized and lungs, 
liver and spleen were isolated.  These data indicate that in vivo disease progression in 
C57BL/6J mice infected with the transposon insertion library followed an acute course of 




	4.2.2 Transposon insertion sequencing and mapping 
	
Our collaborator Dr. Deborah Yoder-Himes performed sequencing of the input 
transposon insertion library to determine transposon insertion density and homogeneous 
coverage of the B. pseudomallei JW280 genome.  Sequencing of the input mutant library 
mapped 1.1268 million reads to the B. pseudomallei 1026b genome and the mapped reads 
showed that 88% percent of genes contained a transposon insertion. Approximately 8% 
of the B. pseudomallei genome is estimated to represent essential genes based on in vitro 
growth [33]; thus our input library coverage approached the maximum potential coverage 
of 92%.  As might be expected, larger genes received better coverage efficiency and 
genes larger than 400 base pairs in length had over 94% coverage (Figure 12A).   
We hypothesized that lung-specific delivery of the B. pseudomallei mutant library 
would sustain selective pressure in the lung, which would lead to an initial loss of library 
diversity and subsequent additional diversity loss following spread to the liver and 
spleen.  Tn-seq analyses typically investigate changes in library diversity between two 
conditions using a 2-fold cutoff criteria [85, 113, 114], however, given the smaller size of 
our mutant library tailored for animal infection studies, we increased the stringency of 
our initial data analysis to a 3-fold cutoff.  Sequencing of the output libraries showed that 
at a 3-fold loss relative to the input library, transposon mutants in the lungs sustained 
selective pressure leading to clearance of 1455 transposon-inactivated genes required for 
lung colonization (Figure 12B).  As expected, the transposon library was further reduced 
in the spleen (2862 genes), suggestive of loss of library diversity both in the lung and due 
to loss of genes required for disseminated spread.  Surprisingly, we observed a greater 
retention of diversity of the transposon library in the liver relative to the lung (765 
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mutants lost in the liver compared to 1455 in the lung), suggesting that a representative 
library pool reached this site prior to effects of the selective pressure exhibited in the lung 
(Figure 12B).  Further, the retention of library diversity in the liver relative to the lung 
suggests that the liver does not exhibit as strong a selective environment as the lung, and 
that the early spread to the liver is at high titer so as to avoid potential bottlenecking 
effects of spread from one tissue to another.  Taken together, these data suggest that B. 
pseudomallei spread from the lung to the liver is a prominent dissemination path, which 
occurs as an early event resulting in reduced selective pressure in the liver. 
 
4.2.3 Burkholderia pseudomallei early hepatic dissemination 
	
To characterize the kinetics of disseminated spread from the lung, a time course 
analysis was conducted.  Groups of three C57BL/6J female albino mice with 104.62 CFU, 
isolated lungs, liver and spleen at 6, 12 and 24 hours post infection and enumerated 
bacterial numbers from each organ.  Transposon mutants were cultured from the lungs 
with higher numbers than the original instilled amount by 6 hours, and grew 
exponentially throughout the course of infection (Figure 13), consistent with growth 
patterns observed by optical diagnostic imaging (Figure 11A).  At 6 hours post infection, 
transposon mutants were also present in the liver at similar numbers to those found in the 
lungs (Figure 13), confirming the findings of the Tn-seq data that hepatic spread is early 
and at high titer.  Colonization of the spleen was detected by 12 hours post infection at or 
below the limit of detection (100 CFU), where pronounced splenic colonization occurred 
24 hours post infection (Figure 13).  This suggests that the enhanced loss of Tn-seq 
library diversity in the spleen relative to the lung is associated with later spread from the 
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lung, subsequent to the effects of selective pressure in the lung.  Thus, B. pseudomallei 
colonize host lungs very early during infection and persist at this site through the onset of 
acute respiratory disease.  Similarly, bacteria can spread from the lungs at high titers to 
colonize the host liver very early following infection but bacterial numbers at this site 
remain constant until late in infection.  This finding corroborates a unique observation 
made from the Tn-seq data set, shedding new light on B. pseudomallei dissemination. 
 
4.2.4 Identification of virulence determinants required for Burkholderia 
pseudomallei colonization of host lungs 
	
We initially focused our analysis of the Tn-seq data set on identifying virulence 
determinants required by B. pseudomallei to colonize the lungs of mammalian hosts, of 
which 1455 genes were required to colonize the murine lung at a 3-fold relative 
abundance cutoff ratio relative to the input pool (Figure 12B).  As a refined stringency to 
focus our identification of key virulence determinants, we made use of a targeted analysis 
of the capsular polysaccharide (CPS or CPS I [115]) biosynthetic cluster.  We have 
previously demonstrated that a capsule mutant was attenuated 6.8-fold relative to the 
isogenic parent strain in the IMIT model, but that this level of attenuation was not 
statistically significant [78]. We therefore performed a detailed analysis of the Tn-seq 
lung results for the CPS I biosynthetic cluster as a benchmark genetic system, which 
exhibits a marginal level of attenuation by LD50 analysis.  We found that while the 
majority of CPS I genes were reduced in the lung relative to the input pool, pronounced 
variation in degree of response was observed across the genetic cluster (Figure 14).  This 
variation was suggestive of bottlenecking effects, which are possible under the 
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parameters of the current study, which was designed for a biologically relevant infection 
while achieving saturating library coverage.  While variation was observed across the 
CPS I locus, the locus itself exhibited an average 14.92-fold reduction in mutant 
prevalence for the lung versus input pool.  Thus to further analyze the Tn-seq lung data 
set, we applied a more stringent fold-change cut off of 15-fold, reflecting the magnitude 
of the average fold gene reduction of the CPS I locus.  Further, we decided to identify 
clusters of genes, which meet this 15-fold cutoff to mitigate the impact which 
bottlenecking might have on dataset variation at the individual gene level.  
A total of 548 genes underwent selective pressure in the lung at a 15-fold cutoff 
relative to the input pool.  These genes were heat mapped for nearest neighbor 
relationship (Figure 15) to identify genetic clusters with consecutive hits of no more than 
a 4-gene distance from the previous hit.  The three genetic loci which provided the largest 
assemblage of genes meeting these criteria included: i) CPS I (8 genes), ii) Type 6 
Secretion System cluster 5 (T6SS5; 8 genes), and iii) Type 3 Secretion System cluster 3 
(T3SS3; 7+5 genes) (Table 2).  The T6SS5 is identified as cluster 5 by the NCBI 
database [69], and this same cluster is identified as cluster 1 in Burkholderia mallei [116]. 
Numerous additional small genetic clusters may provide important contributions to the 
fitness of B. pseudomallei in the lung.  However, these data indicate that the three 
prominent genetic systems contributing to B. pseudomallei lung pathogenesis are CPS I, 
T3SS3 and T6SS5.  Given that we have previously characterized the contribution of CPS 
I and T3SS3 to respiratory melioidosis using the IMIT model [78], we decided to address 
the impact of the T6SS5 system on B. pseudomallei virulence. 
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Only a single gene met the 15-fold cutoff criterion in the liver (thioredoxin: -16.2-
fold reduced), suggesting that the liver does not offer a strong selective pressure against 
B. pseudomallei relative to that of the lung.  Conversely, 2255 genes met this more 
stringent 15-fold cutoff criterion in the spleen, thus this criterion did not effectively 
reduce the number of hits in the spleen from the 2862 hits at a 3-fold cutoff criterion.  
Due to the late spread to the spleen and the large number of gene hits, we interpret that 
the colonization of the spleen in this current model system is a bottle-necked event that 
does not facilitate a biologically relevant data interpretation.  This study therefore 
focused on validating the results from the lung dataset, specifically the identification of 
capsule, T3SS3 and T6SS5 as the largest genetic loci contributing to respiratory 
melioidosis. 
 
4.2.5 T6SS5 mutant is not attenuated in the IMIT model 
	
We previously calculated the LD50 of a B. pseudomallei luminescent strain JW280 
to be 103.87 CFU, a T3SS3 translocation-deficient mutant, JW280 ΔsctUBp3 to be 106.19 
CFU and a CPS I operon mutant to be 104.57 [78].  While CPS I, T3SS3, and T6SS5 all 
contributed to B. pseudomallei pulmonary fitness by the Tn-seq screen, single strain 
challenge with a CPS mutant did not reveal an attenuation by LD50, whereas a T3SS3 
mutant was significantly attenuated >200-fold [78].  We therefore challenged C57BL/6J 
albino female mice with 103.95 CFU of the JW280 luminescent strain and 104.25 CFU of 
the JW280 ΔtssC-5 luminescent T6SS5 mutant strain to investigate the role of T6SS5 in 
respiratory melioidosis.  Infection with the parent JW280 strain close to its LD50 resulted 
in 67% mortality (Figure 16A), whereas infection with the luminescent T6SS5 mutant 
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was 100% lethal with the 104.25 CFU dose, which is 0.52-log above the parent LD50. 
Thus, the LD50 of the tssC-5 mutant is <104.25 CFU, which was not significantly 
attenuated by Log-rank survival analysis relative to the parent control (Figure 16A). 
Therefore, like the CPS mutant, the T6SS5 mutant is not attenuated in a single strain 
respiratory model challenge.  Optical diagnostic imaging was used to monitor bacterial 
proliferation in the lung of lethally infected mice and by 19 hours post infection both the 
parent and the T6SS5 mutant were detectable by bioluminescent imaging.  However the 
bioluminescent signal intensity increased at similar rates in the thoracic cavity (Figure 
16B).  While the T6SS5 mutant appeared to be slightly less fit than parent strain in 
proliferation rate, this difference was not significant.  We characterized the bacterial 
tissue burden in moribund mice and found no significant difference between the T6SS5 
and parent bacterial numbers in the lungs, liver and spleen (Figure 16C-D).  Thus, 
although our Tn-Seq analysis revealed that the T6SS5 cluster is required for the full 
fitness of B. pseudomallei in the lung, single strain pulmonary challenge studies did not 
support this role for T6SS5.  
 
4.2.6 A Burkholderia pseudomallei T6SS5 mutant is attenuated in competition 
studies 
	
Given that Tn-Seq is a genome-wide competition study, and initial validation of 
our Tn-Seq results using traditional LD50 estimations did not identify attenuation for the 
tssC-5 mutant, we decided to investigate whether this T6SS5 mutant is attenuated by 
direct competition studies.  We generated a novel gentamicin-marked PtolCluxCDABE 
bioluminescence reporter strain, MGBP001, which we also generated for the CPS I, 
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T3SS3 and T6SS5 mutants and used these in competition studies against gentamicin-
sensitive, non-luminescent, DD503.  Accordingly, four groups of three C57BL/6J albino 
female mice were inoculated with ~104.0 B. pseudomallei at a 1:1 ratio of DD503 
combined with either: i) MGBP001, ii) MGBP001 Δwcb (CPS I-), iii) MGBP001 
ΔsctUBp3 (T3SS3-), or iv) MGBP001 ΔtssC-5 (T6SS5-).  Infections persisted for 67 hr 
(late stage disease) before lungs, liver and spleen were collected and homogenates 
differentially plated on agar to identify proportions of gentamicin resistant and sensitive 
strains.  The MGBP001 parent strain exhibited a competition index which was not 
significantly different from a ratio of 1.0 (Figure 17A), indicating that DD503 and 
MGBP001 shared the same virulence potential in all tissues, suggesting that neither the 
luminescence operon nor gentamicin resistance impact the virulence of B. pseudomallei.  
Interestingly, all three mutant strains exhibited significantly reduced competition indices 
in the lungs, liver and spleen of mice relative to the non-luminescent DD503 competition 
partner (Figure 17A).  Furthermore, optical diagnostic imaging of the thoracic cavity 
demonstrated that the parent MGBP001 strain proliferated within the lung (Figure 17B), 
consistent with the pulmonary colonization observed by the JW280 strain [78].  Imaging 
was able to successfully monitor the decreased fitness of the three mutants in the lung 
during the course of infection (Figure 17B), with significant differences in 
bioluminescence for all but the capsule mutant by 39 hr, and for all strains by 50 hr, 
indicating that optical diagnostic imaging can be used to monitor fitness defects in vivo 
during competition studies.  Therefore, CPS I, T3SS3, and T6SS5 are all critical 
virulence determinants to support the fitness of B. pseudomallei in the lung, but 
importantly, attenuation of these virulence systems by single strain challenge studies has 
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only been able to identify a role for T3SS3.  We propose that competition analyses, 
including Tn-seq, provide a higher resolution assay by which to assess the role of B. 
pseudomallei virulence determinants in the lung, and that our current Tn-seq screen 
successfully identified CPS I, T3SS3 and T6SS5 as the largest genetic loci required to 




In this study, we performed Tn-seq analysis to identify virulence determinants 
required to cause respiratory disease in a mouse model of lung-specific melioidosis.  The 
primary design criteria of our screen were achieving the balance of saturating transposon 
mutagenesis while also limiting the challenge dose to allow for a biologically relevant 
disease progression.  Previous transposon-directed insertion site sequencing and Tn-seq 
libraries have been generated in the Burkholderia pseudomallei strain K96243 [33] and 
its close relative Burkholderia thailandensis [111, 112] to identify essential genes 
required for survival of these pathogens in vitro.  Importantly, these in vitro screens 
allowed for much larger library sizes to accurately identify essential genes which were 
not amenable to transposon mutagenesis, which for B. pseudomallei was estimated to be 
8.0% of the genome [33].  In spite of limiting library size in our study to allow for 
infection studies, we achieved coverage of 88% of the genome, where the theoretical 
maximum coverage is 92% based on estimates of number for essential genes.  Thus, we 
achieved near saturating coverage of the genome while still challenging mice with <10 
LD50s of bacteria.   
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An unexpected result of our Tn-seq dataset was the revelation that B. 
pseudomallei is capable of reaching the liver very early in the course of infection, which 
was subsequently validated by a time course infection study.  These findings were 
facilitated by using IMIT instillation which has been reported to efficiently deliver ~98% 
of an instilled dose directly into the lung [77].  Within 6 hrs of delivery directly into the 
lung by IMIT instillation, B. pseudomallei not only replicates in the lung, but also spreads 
to the liver at numbers similar to that cultured from the lung.  Interestingly, few genes 
were critical for B. pseudomallei to maintain a presence in the liver, relative to the lung, 
suggesting that the lung does not persistently seed the liver over the course of infection, 
nor is the liver a source of a strong selective pressure to B. pseudomallei.  Furthermore, 
B. pseudomallei does not appear to replicate in the liver until late in the infection, 
suggesting that the systemic fitness of the host may impact the replication potential of B. 
pseudomallei in the liver, again given that Tn-seq results do not support the possibility 
that the late infection increase in hepatic burden results from spread from the lung.  It is 
noteworthy that in other respiratory models, the liver becomes colonized at later time 
points; for instance, aerosol delivery of B. pseudomallei did not result in detection of 
bacteria in the liver until 3 days post infection [117].  Thus, the observation of rapid 
dissemination from the lung to the liver may be a unique feature of the IMIT model, as is 
the prominent moribund septicemia, which is not observed in other respiratory 
melioidosis models.  Future work will be required to understand the role of the liver as a 
replicative niche for B. pseudomallei during respiratory melioidosis. 
We developed a high specificity filter to prioritize follow-up analysis of the Tn-
seq results of the lung.  The selection criteria was benchmarked to the capsule 
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polysaccharide genetic locus which we previously demonstrated was not a critical 
virulence determinant in the IMIT model of respiratory melioidosis, yet was attenuated 
6.8-fold relative to parent [78].  Thus, our criteria were chosen to capture all virulence 
systems, including those that may not be significantly required by LD50 analysis. Our 
screen identified 548 genes, 8.7% of the genome’s predicted open reading frames 
(ORFs), to be required by the bacterium for mammalian lung colonization, and of these, 
32% (175 ORFs) accounted for hypothetical proteins, suggesting that additional novel 
virulence systems may participate in mediating fitness within the mammalian lung.  
Using cluster analysis to further prioritize the Tn-seq data set, we identified the three 
dominant genetic loci contributing to respiratory melioidosis as CPS I, T3SS3 and 
T6SS5.  Interestingly, these systems have been previously identified as virulence systems 
in systemic animal models [19, 61, 70]; however, other virulence determinants described 
as important in systemic disease models did not meet our selection criteria, including the 
lipopolysaccharide (LPS) biosynthetic locus which had just two genes meeting our 15-
fold selection criterion.  Thus, virulence determinants required to support systemic 
infection might not be the same as those required in the lung.  Our Tn-seq analysis was 
notably biased to the identification of large genetic systems, which contribute to 
respiratory melioidosis, and it is therefore likely that additional genetic loci have also 
been identified by this Tn-seq dataset, which will be the subject of future investigation.   
Most B. pseudomallei virulence factors have been characterized primarily in 
systemic infection models, including intravenous, subcutaneous, and intraperitoneal 
inoculation.  Indeed, the three major virulence systems targeted from our Tn-seq screen 
have been well studied as major contributors to disease in hamster and mouse systemic 
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intraperitoneal infection models.  The capsular polysaccharide has been characterized by 
several groups as providing one of the most significant contributions to the systemic 
disease potential of B. pseudomallei, with capsule mutants being attenuated 
approximately 5-log in these infection models [59, 62].  The significant role for capsule 
in B. pseudomallei systemic disease is consistent with a demonstrated role of this 
virulence factor in resisting complement opsonization of the bacteria [59], and therefore 
likely a critical virulence factor for traffic between tissues, suggestive of B. pseudomallei 
spread as an extracellular pathogen.  Interestingly, the capsule mutant does not appear to 
have a major role in the respiratory system of mice with attenuation levels of <2 log by 
intranasal delivery and <1 log by IMIT instillation [60, 78].  Importantly, the T3SS3 
system is known to allow for escape of B. pseudomallei from phagosomes to facilitate 
rapid replication in the cytoplasm of phagocytes [38], and the ubiquitous requirement for 
T3SS3 in both systemic [19] and respiratory disease models [78] suggests that the 
intracellular lifestyle of B. pseudomallei is critical in all host tissues.  Indeed, T3SS3 is 
the only virulence system examined thus far in the IMIT instillation method that exhibits 
significant attenuation by single strain challenge, suggesting that this virulence system is 
one of the most critical systems for both respiratory and systemic disease.  The primary 
function of the T6SS5 system is not well described, though there is evidence that T6SS5 
supports the intracellular lifestyle of B. pseudomallei and cell-to cell spread [118, 119]. 
T6SS5 system mutants are attenuated >3 log in a systemic hamster intraperitoneal model 
[118] and are attenuated ~2-3 log in intranasal murine models [119, 120].  In this current 
study, the role for T6SS5 in respiratory melioidosis using IMIT delivery does not appear 
to be a prominent role given that we were unable to demonstrate significant attenuation in 
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single strain challenge studies, which is in contrast to what has been previously reported 
for the intranasal models.  We have previously demonstrated that intranasal inoculation 
of B. pseudomallei in mice results in a moribund disease state primarily associated with 
the nasal cavity rather than the systemic disease state observed following IMIT 
inoculation [78].  Thus, T6SS5 may be an important virulence factor for nasal cavity 
colonization, but does not play the same critical role in the lung as seen for the T3SS3 
system. 
A key finding of our studies was the ability of competition studies to provide a 
higher resolution identification of virulence factors in the fitness of B. pseudomallei in 
the lung than single strain challenges/LD50 analyses.  Similar findings have been made 
for other disease model systems, where competition indexes provide a higher resolution 
methodology for defining the contribution of virulence genes to a pathogen’s fitness in 
animal model systems [121-123].  We had previously reported that a CPS I mutant was 
not significantly attenuated by LD50 in the IMIT model [78], but presently that CPS I was 
significantly attenuated by competition study in the IMIT model.  Similarly, we were 
unable to validate a significant attenuation for a T6SS5 mutant by single strain challenge, 
but identified a significant attenuation by competition index.  The Tn-seq screen itself is a 
genome wide competition assay, thus our competition studies were able to successfully 
recapitulate the phenotypes we identified from the Tn-seq screen results.  However, 
single strain challenges did not have the resolution to defined roles in respiratory 
melioidosis to either capsular polysaccharide or T6SS5.  These observations indicate that 
competition studies have a higher resolution to ascribe roles in virulence to both CPS I 
and T6SS5 in respiratory melioidosis, and thus far, T3SS3 is the sole virulence 
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determinant which exhibits attenuation by LD50 in the IMIT respiratory melioidosis 
model [78].  As an added feature of our competition assay, we have included a unique 
optical imaging approach which is further capable of detecting significant fitness defects 
in competition studies as early as 39 hrs post infection. 
In summary, we provide the first phenotypic screen for B. pseudomallei virulence 
factor function in the mammalian lung, and have identified the largest critical genetic 
systems as CPS I, T3SS3 and T6SS5.  While previously identified as virulence systems, 
this study represents the first comparative study to identify these as the primary genetic 
systems for respiratory melioidosis.  These virulence systems therefore represent 






Figure 11. In vivo disease progression of Burkholderia pseudomallei Tn-seq
 
transposon library.  (A) In vivo growth of the B. pseudomallei transposon library in the 
thoracic cavity of three C57BL/6J female albino mice infected by IMIT was monitored 
twice daily with an in vivo imaging system using luminescence as a read out for bacterial 
replication. Total luminescence was enumerated using a region of interest (ROI) centered 
on the thoracic cavity.  The dashed line indicates technical 95% limit of detection.  (B) 
Whole body imaging of moribund C57BL/6J mice infected with B. pseudomallei 
transposon library at 66 hours post infection. The logarithmic scale bar is provided for the 





Figure 12.  Gene size distribution of the Burkholderia pseudomallei genome and 
transposon insertion coverage.  (A) Histogram of the B. pseudomallei genome (green 
bars) and percentage of genes lacking transposon insertions (brown bars), both binned at 
100 bp gene size intervals.  (B) Tn-seq data sets were analyzed for B. pseudomallei Tn-
seq mutants lost by selective pressure in the lung (1455); liver (765); spleen (2862) at a 3-
fold reduction in relative abundance relative to the input pool.  Venn diagram illustrating 





Figure 13. Burkholderia pseudomallei Tn-seq transposon library tissue burdens at 
key sites of infection.  Groups of three C57BL/6 female albino mice infected with the B. 
pseudomallei Tn-seq transposon library were euthanized at 6, 12 and 24 hours post 
infection.  Bacterial numbers in the lungs, liver and spleen were enumerated by plate 
counting and compared to bacterial numbers of moribund mice at 66 hours post infection 
from the initial Tn-seq transposon library challenge.  A dashed line indicates the limit of 
detection of bacterial enumeration from host tissues.  Tissue counts below the limit of 
detection were set to the limit of detection for statistical analysis.  Statistical significance 
was calculated by Two-way ANOVA followed by Bonferroni post test (**, P<0.01; ***, 





Figure 14.  Analysis of variation within capsular polysaccharide I operon genes 
required for lung colonization by Tn-seq.  (A) Scale representation of the capsular 
polysaccharide genetic locus.  (B) Variation in fold-change of capsule genes by Tn-seq 
analysis of the lung data set relative to the input pool.  The average fold reduction across 






Figure 15.  Proximity heat map of genes required for respiratory melioidosis.  The 
Tn-seq lung data set was filtered for genes required by B. pseudomallei at a 15-fold 
reduction cut off relative to the input pool (548 genes).  Genes were sorted for their 
arrangement on the two circular chromosomes of the B. pseudomallei genome, with 
similar distribution density found on the larger chromosome 1 (309 genes) and smaller 
chromosome 2 (239 genes).  The heat map provides graphical cluster analysis of gene hits 
located in close proximity (red = 1 gene distance) or distal hits (green >70 gene neighbor 
distance). The three largest genetic clusters of hits separated by no more than 4 genes per 
hit are indicated: capsular polysaccharide (CPS I), Type 3 Secretion System cluster 3 





Figure 16.  In vivo characterization of a T6SS mutant.    (A) Survival curve of 
C57BL/6 female albino mice by IMIT infected with either JW280 or JW280 ΔtssC-5. (B) 
In vivo growth of B. pseudomallei strains JW280 and JW280 ΔtssC-5 infecting C57BL/6 
mice, where bioluminescence was monitored twice per day and thoracic cavity total flux 
(p/s) was collected from region of interest measurements.  A horizontal dashed line 
indicates the technical 95% limit of detection.  Bacterial numbers in the lungs (C), liver 
(D) and spleen (E) of C57BL/6 mice infected with either JW280 or JW280 ΔtssC-5 were 
enumerated by bioluminescence measurements of ex vivo tissues, as described [77].  






Figure 17.  Burkholderia pseudomallei major virulence determinants are attenuated 
in competition assays.  (A) Competitive index of luminescent, Gm-marked parent strain 
(MGBP001), capsular polysaccharide deletion mutant (MGBP001 Δwcb), T3SS3 
(MGBP001 ΔsctUBp3) and T6SS5 (MGBP001 ΔtssC-5) mutants compared to Gm-
sensitive, non-luminescent strain, DD503.  Competitive index was calculated as the 
output ratio of mutant to parent divided by the input ratio of mutant to parent, having 
differentially plated lung, liver and spleen homogenates on agar plates with or without 
gentamicin selection.  The horizontal dashed line indicates a competitive index of 1.  
Statistical significance was calculated using One-way ANOVA followed by Tukey’s 
Multiple Comparison Test (*, P<0.01; **, P<0.001; ***, P<0.0001).  (B) In vivo growth 
of MGBP001, MGBP001 Δwcb, MGBP001 ΔsctUBp3 and MGBP001 ΔtssC-5 in the lungs 
was monitored twice daily using luminescence as a read out for bacterial replication, and 
total flux (p/s) measurements collected from regions of interest centered on the thoracic 
cavity.  The horizontal dashed line indicates the 95% technical limit of detection.
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Table 3.  Identification of prominent genetic loci required for pulmonary disease. 
Feature ID Fold change Distance to 
previous hit 
Feature ID Fold change Distance to 
previous hit 
T3SS3   T6SS5   
bprA -70.3781  BP1026B_II1587 -83.2298  
bipC -35.0191 1 hcp-5 -367.19 4 
bipB -15.6668 1 tssF-5 -22.3609 3 
bicA -15.2996 1 clpV-5 -23.6294 1 
bsaZ -56.991 1 tagB-5 -21.4194 3 
spaP -15.6396 3 tagC-5 -22.6434 1 
bsaV -26.665 1 tssK-5 -31.7466 2 
bsaO -82.8959 7 tssL-5 -111.177 2 
BP1026B_II1643 -34.0416 2 Capsule   
BP1026B_II1644 -59.6684 1 wcbF -36.6525  
BP1026B_II1645 -40.3909 1 wcbG -25.4066 2 
BP1026B_II1646 -33.6591 1 wcbI -36.413 3 
   wcbL -52.5586 3 
   wcbM -65.6182 2 
   wcbQ -24.1121 4 
   wcbS -25.4738 2 




TYPE 3 SECRETION SYSTEM CLUSTER 3 EFFECTORS MEDIATE 





 The type 3 secretion system (T3SS) is a needle-like apparatus that translocates 
effector proteins across both Gram-negative bacterial membranes into the cytoplasm of 
host cells [42, 43].  T3SS translocated effectors from several Gram-negative bacteria such 
as S. flexneri [124], S. enterica [125] and P. aeruginosa [126], interact with host cell 
proteins to subvert the cell’s signaling pathways facilitating bacterial survival within this 
intracellular niche.  In its genome, B. pseudomallei encodes for 3 T3SS loci [45, 46], yet 
cluster 3 (T3SS3) is the only cluster that plays an important role in the intracellular life 
cycle of the bacterium in mammalian cells, specifically by promoting vacuolar escape 
from endocytic vesicles [36] and overall intracellular fitness of the bacterium [38, 127].   
B. pseudomallei like many other cytosolic pathogens, have evolved to rapidly 
escape from endocytic vesicles by using its T3SS, following internalization into host cells 
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[35].  Escape of the bacterium from the vacuolar compartment is a critical step for 
intracellular survival [38] and is estimated to take place within 3 hours of internalization 
[38].  However vacuole acidification occurs within 15 minutes of vacuole formation 
[128], suggesting that vacuolar escape occurs earlier, as is the case with S. flexneri, which 
escapes the vacuole in less than 10 minutes post internalization [129].  Once in the 
cytoplasm, B. pseudomallei establishes a replicative niche by manipulating host immune 
responses and signaling pathways to the bacterium’s advantage through the concerted 
action of its T3SS3 translocated effectors [38].  Ultimately, B. pseudomallei lyses its host 
spreading to neighboring cells and continuing the cycle of infection (Figure 2) [35]. 
The contributions of B. pseudomallei T3SS3 effectors to vacuolar rupture of the 
bacterium are poorly understood, yet their concerted functions are critical for the 
bacterium’s intracellular survival [36, 38, 48-50, 55, 56].  Putative B. pseudomallei 
T3SS3 translocated effectors (Table 4) include the Burkholderia outer proteins BopA, 
BopC and BopE and the Burkholderia secretion apparatus (Bsa) associated proteins 
BapA, BapB and BapC [38].  Of great significance is that the T3SS3 effector BopA is 
required for vacuolar rupture and rapid escape of B. pseudomallei from endocytic 
vacuoles, as bopA mutants exhibit delayed vacuolar escape from phagosomes, leading to 
decreased intracellular survival in RAW264.7 macrophages [36].  Other than BopA, no 
role in vacuolar escape has been attributed to any other T3SS3 protein effectors.  BopC 
and BopE may play a role in invasion of non-phagocytic cells, as inactivation of both 
effectors has been associated with a significant reduction in invasion of non-phagocytes 
[48, 56].  A role of BopE in invasion of non-phagocytic cells as a guanine nucleotide 
exchange factor (GEF) is consistent with the roles of its Salmonella T3SS orthologues 
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SopE and SopE2, which act as GEFs for the Rho GTPases Cdc42 and Rac1, facilitating 
invasion of host cells through actin network rearrangements [130].  Yet, activity of BopE 
for these GTPases is much lower than that of SopE or SopE2 and notably B. 
pseudomallei is only weakly invasive, suggesting that BopE may target other host 
GTPases involved in distinct signaling pathways.  Both BapA and BapC are secreted in 
vitro in a T3SS3-dependent manner, but their effector functions during infection of host 
cells remain elusive [55].  While, BopA is the only T3SS3 effector protein that appears to 
directly contribute to B. pseudomallei vacuolar escape, escape of a bopA mutant is only 
delayed and not completely abrogated to levels of secretion-defective mutants, strongly 
suggesting that other T3SS3 effectors may also be involved in mediating the efficient 
escape of B. pseudomallei from phagosomes [36, 38].  
We hypothesize that additional B. pseudomallei type 3 secretion effectors may 
possess distinct and complementary functions resulting in the bacterium’s rapid escape 
from host cell endocytic vacuoles and full virulence in host cells.  Yet, the contributions 
of B. pseudomallei T3SS3 effectors to vacuolar rupture remain elusive, yet their 
concerted functions are critical for the bacterium’s intracellular fitness [36, 38, 48-50, 55, 
56].  Accordingly, herein we assess the growth kinetics of the B. pseudomallei T3SS3 
effector mutants bopA, bopC, bopE, bapA and bapC in cultured macrophages to 
investigate their impact on intracellular survival of the bacterium.  We demonstrate that 
the five profiled effectors facilitate full virulence of B. pseudomallei in cultured 
macrophages.  Finally, we investigate the role of a host cell protein with functions in 
vesicular trafficking, which is potentially targeted for BopA activity, and propose a 
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mechanism by which BopA interaction with this host factor results in the rapid escape of 
B. pseudomallei to the cytoplasm of host cells. 
 
5.2 Results 
5.2.1 Real-time growth kinetics of bioluminescent Burkholderia pseudomallei in 
cultured macrophages 
 We developed a high-sensitivity assay to assess the fitness of intracellular B. 
pseudomallei in cultured macrophages.  We used the bioluminescent B. pseudomallei 
parental strain JW280, which contains a chromosomal insertion of the Photorhabdus 
luminescens luxCDABE operon and exhibits constitutive light production during in vivo 
and in vitro infections, allowing for the monitoring of bacterial numbers during 
intracellular replication [64].  To assess the fitness of intracellular B. pseudomallei, we 
infected J774A.1 cultured macrophages with JW280 and monitored the progression of 
infection for ~14 hours.  Macrophages were infected at multiplicities of infection (MOI) 
of 5, 2, 0.5 and 0.2 in a 96-well plate format with gentamicin added to the culture media 
at 1-hour post infection and maintained throughout the assay.  Using in vivo optical 
diagnostic imaging, we observed killing of the B. pseudomallei parental strain very early 
in infection following addition of gentamicin to the culture medium, suggestive of killing 
of extracellular bacteria.  This early loss of bioluminescence was immediately followed 
by a logarithmic growth phase, which peaked between 8.5 hours to >13 hours depending 
on the MOI.  Following the peak in bioluminescence, we observed a marked decrease in 
bacterial bioluminescence, suggestive of macrophage cell death resulting in exposure of 
bacteria to the gentamicin maintained in the culture media (Figure 18).  These findings 
	 97	
are consistent with previous results that showed corresponding growth patterns of non-
luminescent [38, 127] and luminescent [64] B. pseudomallei parental strains.  
Accordingly, we demonstrate that by using in vivo optical diagnostic imaging we can 
accurately track the progression of bioluminescent B. pseudomallei infection in host cells 
in real-time at very high resolution, and that this approach is amenable for use to study 
the progression of infection of distinct B. pseudomallei bioluminescent strains. 
 
5.2.2 A bioluminescent T3SS3 structural mutant exhibits a significant fitness defect 
during infection of host cells  
	 The B. pseudomallei type 3 secretion system structural mutant sctU (bsaZ) is 
incapable of intracellular replication in cultured macrophages due to its impaired ability 
to escape from endocytic vesicles in these cells prior to 12 hours post infection [38, 60].  
Accordingly, we assessed whether the bioluminescent T3SS3 structural mutant JW280 
ΔsctUBp3, was similarly defective in intracellular replication as measured by 
bioluminescence.  We infected J774A.1 cultured macrophages with the parental strain 
JW280 or JW280 ΔsctUBp3 at an MOI of ~3 in a 96-well plate format for ~14 hours using 
a gentamicin protection assay.  Gentamicin was added to the culture media in each well at 
1 hr post infection and maintained throughout the duration of the experiment.  As 
expected, the growth kinetics of the parental strain showed an initial period of bacterial 
loss succeeded by a logarithmic growth-phase that peaked and quickly decreased, 
suggestive of macrophage cell death resulting in exposure of bacteria to antibiotic in the 
culture media.  Inactivation of the structural component sctU in the T3SS3 apparatus 
resulted in minimal intracellular replication of the mutant strain in J774A.1 macrophages 
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prior to 12 hours post infection (Figure 19), as previously reported [38, 127].  This 
reduction in intracellular replication of JW280 ΔsctUBp3 is consistent with the mutant’s 
inability to escape from macrophage phagosomes, as previously described [60].  
However, the sctU mutant is capable of minimal intracellular replication after 12 hours 
post infection, suggestive of delayed vacuolar escape, consistent with previous 
observations, which demonstrated that a sctU mutant is capable of escaping endocytic 
vesicles and replicating in the cytoplasm of cultured macrophages after 12 hours post 
infection [127].  Accordingly, this study confirms prior findings that demonstrate that a 
functional T3SS3 apparatus is critically required for the intracellular fitness of B. 
pseudomallei in cultured macrophages.  Most importantly, these results validate that in 
vivo optical diagnostic imaging is capable of distinguishing phenotypic differences in 
intracellular bacterial viability as a non-invasive approach to study intracellular fitness of 
B. pseudomallei and other intracellular pathogens.  
 
5.2.3 T3SS3 effector proteins are required for full virulence of Burkholderia 
pseudomallei in host cells 
  Full virulence of B. pseudomallei during infection of host cells is dependent on 
the functions of the T3SS3 effector proteins [36, 48, 55, 56].  Notably, inactivation of the 
T3SS3 effector gene bopA results in delayed escape of B. pseudomallei from phagosomes 
of RAW264.7 macrophages, observed by transmission electron microscopy, 
demonstrating that BopA is critical for the bacterium’s rapid vacuolar escape and 
intracellular fitness in cultured macrophages [36].  In order to assess the contributions of 
other Bop and Bap proteins to the intracellular fitness of B. pseudomallei, we infected 
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J774A.1 macrophages with the bioluminescent B. pseudomallei parental strain JW280 or 
the bioluminescent T3SS3 effector mutants bopA, bopC, bopE, bapA and bapC at 
matched multiplicities of infection in a 96-well format.  Infections were allowed to 
proceed for ~14 hours, gentamicin was added to the culture media 1 hr post infection and 
maintained throughout the duration of the assay.  The growth kinetics of the parental 
strain did not differ from the previously observed growth patterns (Figures 20 and 21).  
An initial period of bacterial loss followed by a logarithmic growth phase and a marked 
decrease in bacterial viability, as bacteria were exposed to gentamicin in the culture 
media as a result of cell death.  We monitored the growth profiles of the T3SS3 effector-
mutants bapA and bapC in cultured macrophages and noticed that both mutants displayed 
intracellular fitness defects when compared to the parental strain (Figure 20).  Bacterial 
numbers for the bapA and bapC mutants only reached ~87% and ~78% of the parental 
strain intracellular numbers at the peak of their growth phase, respectively (Figure 20).  
In a similar manner, inactivation of bopA, bopC and bopE resulted in intracellular fitness 
defects when compared to the parental strain (Figure 21).  Bacterial numbers for the 
bopA, bopC and bopE mutants only reached ~70%, ~89% and ~80% of the parental strain 
intracellular numbers at the peak of their growth phase, respectively (Figure 21).  These 
results strongly suggest that all the T3SS3 effector proteins contribute to the intracellular 
fitness of B. pseudomallei in cultured macrophages.  Notably, the growth profiles of the 
five T3SS3 effector mutants showed that inactivation of bopA, bopE or bapC resulted in 
the most pronounced fitness defects (Figures 20 and 21).  BopA specifically has been 
shown to be involved in vacuolar escape [36], therefore this effector is important for 
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intracellular fitness of B. pseudomallei by potentially directly mediating vacuolar rupture 
during infection of host cells. 
 
5.2.4 BopA exhibits delayed vacuolar escape in cultured macrophages 
Previous observations through transmission electron microscopy demonstrated 
that inactivation of bopA results in delayed escape of B. pseudomallei from endocytic 
vesicles from cultured macrophages [36].  We showed that inactivation of bopA results in 
a significant defect in intracellular survival of B. pseudomallei in cultured macrophages.  
Accordingly, we aimed to validate the role of the B. pseudomallei T3SS3 effector BopA 
in vacuolar escape in host cells by determining the subcellular distribution of a bopA 
mutant strain early in infection.  In this assay, we used the B. pseudomallei acapsular 
JW270 strain, which is internalized by macrophages at comparable levels to those of he 
parental strain, is capable of replicating at equivalent numbers to those of the parental 
strain by ~8 hours post infection [60, 64] and has been validated for intracellular survival 
assays at Biosafety Level 2 containment [131].  We infected RAW264.7 macrophages 
with JW270-GFP (MGBP002), or with isogenic bopA and sctUBp3 mutants, MGBP002 
ΔbopA and MGBP002 ΔsctUBp3, respectively.  RAW264.7 cells were seeded on glass 
coverslips for later visualization by confocal microscopy.  The infection was conducted 
in a 24-well format for 2 hours, gentamicin was added to the media culture at 1 hour-post 
infection and maintained through the duration of the experiment.  Extracellular bacteria 
were labeled after infection, followed by selective permeabilization of the cells’ plasma 
membrane with digitonin to label cytoplasmic bacteria and differential antibody staining 
was assessed by confocal microscopy to quantify subcellular B. pseudomallei strains.  We 
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observed that ~40% of the parental strain MGBP002 was present in the cytoplasm of host 
macrophages at 2 hours post infection (Figure 22), consistent with previous estimations, 
showing that ~39% of wild type B. pseudomallei was found in the cytoplasm of 
RAW264.7 macrophages at 2 hours post infection [36].  As expected, MGBP002 
ΔsctUBp3 displayed a significant delay in escape when compared to the parental strain, 
~20% less cytoplasmic numbers than that of the parental strain.  This is consistent with 
previous reports demonstrating that a T3SS3 structural mutant exhibits significant delay 
in escape from RAW264.7 phagosomes [36].  Intracellular numbers of MGBP002 ΔbopA 
were comparable to those observed for the MGBP002 ΔsctUBp3 structural mutant and 
remained trapped at significantly higher levels relative to the parental strain in endocytic 
vacuoles of RAW264.7 macrophages at 2 hours post infection (Figure 22).  This is also 
consistent with reduced numbers of the bopA mutant when compared to the parental 
strain at later times in infected J774A.1 macrophages observed by optical diagnostic 
imaging, likely due to delayed escape from endocytic vesicles (Figure 18) as previously 
reported by Gong et al. [36].  Taken together these results demonstrate that the T3SS3 
effector protein BopA directly contributes to the rapid escape of B. pseudomallei from 
host cell endocytic vesicles. 
 
5.2.5 BopA is associated with punctate structures in the cytoplasm of host cells 
 We focused on elucidating the location of BopA in HEK293 cells as inactivation 
of bopA resulted in delayed vacuolar escape in host cells.  A recent report of a yeast-two 
hybrid screen of B. mallei virulence proteins associated with specialized secretion 
systems, identified the host transport protein particle C8 (TRAPPC8) as a potential BopA 
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interaction partner [132].  TRAPPC8 is the mammalian orthologue of the recently 
identified Trs85 subunit of the yeast TRAPPIII complex, which has been implicated in 
mediating membrane expansion in macroautophagy and the cytoplasm to vesicle pathway 
[133].  Accordingly, TRAPPC8 may represent a target for BopA due to its role in 
intracellular vesicular trafficking.  We therefore hypothesized that BopA may localize to 
distinct structures dispersed in the cytoplasm of host cells.  To investigate the subcellular 
location of BopA in host cells, we generated a FLAG-tagged BopA fusion protein and 
transiently expressed this protein in HEK293 cells for 24 hours. Transient transfection of 
the BopA-FLAG fusion protein showed that BopA was associated with punctate 
structures localized to the cytoplasm of HEK293 cells (Figure 23).  Accordingly, 
localization of BopA to puncta in the cytoplasm of host cells supports a potential 
interaction between this effector and vesicle-associated TRAPPC8, which localizes to 
both vacuolar and plasma membranes [134].  
 
5.2.6 Contribution of host transport protein particle C8 to stabilizing the 
Burkholderia-containing vacuole during infection of host cells 
TRAPPs are multi-subunit complexes with guanine nucleotide exchange factor 
activity involved in various vesicular trafficking processes [135].  Accordingly, we 
examined the role of TRAPPC8 during infection of RAW264.7 macrophages with the B. 
pseudomallei JW280 parental strain as BopA may directly interact with this host factor.  
We used siRNA to knockdown TRAPPC8 protein translation in RAW264.7 macrophages 
or we used non-specific scrambled siRNA as a negative control.  Macrophages were 
treated with siRNA for 48 hours and were then infected with JW280 at an MOI of 10.  
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The assay was conducted in a 96-well format and in vivo optical diagnostic imaging was 
used to track the progression of infection for ~15 hours, using a gentamicin protection 
assay.  Growth kinetics of B. pseudomallei in macrophages treated with scrambled 
siRNA exhibited the previously observed growth pattern (Figures 18 and 24), showing 
initial killing of bacteria by 4 hours post infection, followed by a phase of bacterial 
expansion and killing of the host cell by ~ 9 hours post infection (Figure 24).  
Surprisingly, TRAPPC8 knockdown resulted in an early (~2 hours post infection) 
increase in bacterial numbers in infected macrophages, followed by a sharp decrease in 
numbers by 4 hours post infection, likely due to rapid loss of a viable niche for the 
bacteria resulting in exposure to gentamicin in the culture media (Figure 24).  These 
results strongly suggest that absence of TRAPPC8 in host cells due to siRNA knockdown 
results in vacuolar destabilization, releasing B. pseudomallei to the cytoplasm of the cell 
to establish a replicative niche.  These results also suggest that vacuolar destabilization 
through TRAPPC8 function inhibition may constitute a mechanism by which BopA 
promotes the rapid escape of B. pseudomallei from endocytic vesicles and ultimately 




 We used in vivo optical diagnostic imaging to study the growth kinetics and 
overall progression of B. pseudomallei infection in cultured macrophages.  By using 
bioluminescent B. pseudomallei to infect these host cells, we are able to monitor the 
progression of disease noninvasively in a real-time, high-throughput manner and at very 
high resolution.  This high-throughput screen confers great advantages when 
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investigating the impact of specific mutations or treatments on the fitness of diverse 
bacterial strains.  Further, our approach facilitates the examination of the growth kinetics 
of distinct bacterial strains in different primary and cell culture models, at different 
multiplicities of infection and under diverse treatments such as siRNA knockdown or 
small compound libraries.  Because the approach is noninvasive, observations on growth 
kinetics can be made at different time points during infection, minus sample vessel 
manipulation, which may reduce technical error across experimental samples.  Notably, 
B. pseudomallei is classified as a Tier 1 Select Agent in the United States and this 
classification requires experimental use of the bacterium to be conducted under Biosafety 
Level 3 containment, so minimizing manipulation of infected samples maximizes user 
safety and reduces the utilization of laboratory resources such as personal protective 
equipment and other consumables.   
In this study, we investigated the impact of T3SS3 effector proteins on the 
intracellular survival of B. pseudomallei in cultured macrophages and found that all 
effector mutants exhibited defects in intracellular fitness in these cells.  These results 
strongly suggest that T3SS3 effectors act in concert to promote the bacterium’s 
intracellular survival in host cells.  Comparison of the intracellular fitness of the T3SS3 
effector mutants bopA, bopC, bopE, bapA and bapC in cultured macrophages, 
demonstrated that BopA, BopE and BapC play prominent roles during B. pseudomallei 
infection that directly contribute to intracellular survival of the bacterium, and that other 
effectors may have supportive roles to also promote intracellular fitness.  Yet, further 
studies are needed to validate the role of these effectors in primary cells.  In addition, 
finding potential host cell protein targets for BopC, BopE, BapA and BapC would further 
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our understanding of B. pseudomallei pathogenesis and elucidate host proteins and 
pathways exploited by the bacterium to promote its own intracellular survival. 
We focused on studying the role of BopA in facilitating B. pseudomallei’s escape 
from phagocytic vesicles, as bopA mutants exhibited the most profound defect in 
intracellular fitness of all the profiled effectors and this defect was previously 
demonstrated to be a result of delayed escape from host cell phagosomes [36].  The 
trafficking particle protein C8 (TRAPPC8) was identified as a potential host cell target 
for B. mallei BopA [132].  Importantly, TRAPPC8 function may facilitate vacuolar 
trafficking or fusion events important for Burkholderia-containing vacuoles in host cells, 
as siRNA knockdown of TRAPPC8 results in the rapid release of B. pseudomallei from 
vacuoles to the cytoplasm of infected host cells.  TRAPPC8, an orthologue of the Trs85 
subunit of the yeast TRAPPIII complex, is required for macroautophagy and for the 
cytoplasm to vacuole targeting pathway [136].  All three yeast TRAPP complexes 
regulate the Rab GTPase Ypt1, an orthologue of the mammalian GTPase RAB1, through 
their guanine nucleotide exchange factor domain [133] and are required for mediating 
initial tethering events between vesicles and their target membrane [137].  Limited data is 
available on the functions of mammalian TRAPP complexes and the attributed roles of 
these complexes in mammalian trafficking pathways are based on studies of orthologous 
yeast TRAPP complexes [133], although mammalian TRAPP complexes likely regulate 
vesicular trafficking through RAB proteins as well.   
We explored the contribution of TRAPPC8 to B. pseudomallei fitness in cultured 
macrophages.  Our results suggest that TRAPPC8 knockdown results in destabilization of 
vesicular membranes in RAW264.7 macrophages, as evidenced by the rapid increase in 
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B. pseudomallei intracellular numbers in these cells (Figure 24).  Based on TRAPPIII 
functions in yeast, this also suggests that disruption of TRAPPC8 function in the vacuolar 
membrane of Burkholderia-containing vacuoles (BCVs) may inhibit tethering events of 
vesicles to BCVs, subsequent vesicle fusion and membrane expansions events leading to 
vacuolar destabilization.  This is consistent with the role of the human papillomavirus L2 
protein during infection of epithelial cells, which inhibits TRAPPC8 function in the 
Golgi, leading to fragmentation/destabilization of this compartment [134].  We propose 
that BopA binding to TRAPPC8 leads to inhibition of vesicular tethering by masking 
TRAPPC8 from incoming donor vesicles, hindering interaction of the TRAPPIII complex 
with the vesicle (Figure 25).  Another possibility may be that BopA binding to TRAPPC8 
inhibits interaction of TRAPPIII with host effector proteins required for SNARE 
assembly and membrane fusion and expansion at the donor/acceptor vesicle interface 
(Figure 25).  Importantly, co-localization of TRAPPC8 to the Burkholderia-containing 
vacuole would validate this interaction and add to the overall knowledge of mammalian 
TRAPPIII function, the mechanisms involved in tethering and membrane fusion, and host 
factors and pathways exploited by B. pseudomallei to promote its intracellular survival in 
mammalian cells. 
Overall, we demonstrated that we can monitor the progression of B. pseudomallei 
infection in cultured macrophages in a real time, high-throughput manner at very high 
resolution using in vivo optical diagnostic imaging and found that the T3SS3 effectors 
BopA, BopE and BapC greatly contribute to B. pseudomallei’s intracellular survival in 
cultured macrophages. Thus, we provide a novel approach to investigate the contribution 
of both host and pathogen proteins to the establishment of the B. pseudomallei 
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intracellular niche in host macrophages.  Importantly, these studies will help to elucidate 
vesicular trafficking patterns of the mammalian TRAPPIII complex and provide potential 
host or bacterial targets for therapeutics and experimental vaccines for the prevention of 





Figure 18.  Growth kinetics of Burkholderia pseudomallei parental strain in J774A.1 
macrophages.  In vivo growth pattern of the bioluminescent B. pseudomallei parental 
strain JW280 in infected J774A.1 macrophages at multiplicities of infection (MOI) of 5, 
2, 0.5 and 0.2 bacteria per macrophage using a gentamicin protection assay.  Growth of 
B. pseudomallei was followed using in vivo imaging over a 14 hour time period using 
Total Flux (total luminescence) of bacteria in photons per second.  Intracellular bacterial 





Figure 19.  Growth kinetics of the Burkholderia pseudomallei type 3 secretion system 
cluster 3 structural mutant JW280 ΔsctUBp3 in J774A.1 macrophages.  Comparison 
of in vivo growth patterns of the B. pseudomallei parental strain JW280 and JW280 
ΔsctUBp3 mutant strain in infected J774A.1 macrophages.  Growth of B. pseudomallei was 
followed using an in vivo imaging system over a 14 hour time period using Total Flux 
(total luminescence) of bacteria in photons per second.  Intracellular bacterial burden was 







Figure 20.  Growth kinetics of the Burkholderia pseudomallei type 3 secretion system 
cluster 3 effector protein mutants JW280 ΔbapA and JW280 ΔbapC in J774A.1 
macrophages.  Comparison of in vivo growth patterns of the B. pseudomallei parental 
strain JW280 and the effector mutant strains JW280 ΔbapA and JW280 ΔbapC in 
infected J774A.1 macrophages.  Growth of B. pseudomallei was followed using an in 
vivo imaging system over a 14 hour time period using Total Flux (total luminescence) of 
bacteria in photons per second.  Intracellular bacterial burden was plotted as the relative 







Figure 21.  Growth kinetics of the Burkholderia pseudomallei type 3 secretion system 
cluster 3 effector protein mutants JW280 ΔbopA, JW280 ΔbopC and JW280 ΔbopE 
in J774A.1 macrophages.  Comparison of in vivo growth patterns of the B. pseudomallei 
parental strain JW280 with the JW280 ΔbopA, JW280 ΔbopC and JW280 ΔbopE effector 
mutant strains in infected J774A.1 macrophages.  Growth of B. pseudomallei was 
followed using an in vivo imaging system over a 14 hour time period using Total Flux 
(total luminescence) of bacteria in photons per second.  Intracellular bacterial burden was 
plotted as the relative percent of viable bacteria over time.
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Figure 22.  A BopA effector mutant exhibits delayed vacuolar escape in RAW264.7 
macrophages.  (A) Representative confocal images of RAW264.7 macrophages infected 
with the B. pseudomallei strains MGBP002, MGBP002 ΔsctUBp3 or MGBP002 ΔbopA.  
Bacteria were pseudocolored, with extracellular bacteria shown in white (blue, red and 
green transposition) cytoplasmic bacteria shown in yellow (red and green transposition) 
and bacteria in vacuoles shown in green.  (B) Percentage of B. pseudomallei MGBP002, 
MGBP002 ΔsctUBp3 and MGBP002 ΔbopA located in vacuoles of infected RAW264.7 







Figure 23.  Ectopically expressed BopA is associated with punctate structures in the 
cytoplasm of HEK293 cells.  Representative confocal microscopy image of HEK293 
cells transiently transfected with p3XFLAG-BopA for 24 hrs.  (A) BopA-FLAG fusion 
protein was detected in the cytoplasm of HEK293 cells with an anti-FLAG Alexa Fluor 











Figure 24.  TRAPPC8 knockdown promotes intracellular survival of Burkholderia 
pseudomallei’s in RAW264.7 macrophages.  Growth kinetics of the B. pseudomallei 
JW280 parental strain in infected RAW 264.7 macrophages treated with siRNA against 
TRAPPC8 (yellow line) and scrambled siRNA (pink line) for 48 hours prior to infection.  
Growth of B. pseudomallei was followed using an in vivo imaging system over a 15 hour 
time period using Total Flux (total luminescence) of bacteria in photons per second.  
Intracellular bacterial burden was plotted as the Total Flux of bacteria over time.
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Figure 25.  Model for BopA inhibition of TRAPPC8 function.  Model for interaction 
of the T3SS3 effector BopA and TRAPPC8 at the donor vesicle and acceptor vacuole 
interface in the cytoplasm of host cells during B. pseudomallei infection.  BopA binding 
of TRAPPC8 may interfere with early vesicle tethering events or formation of multi-
subunit fusion complex formation, inhibiting vesicle expansion and leading to vacuolar 
destabilization. 
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BopA Yes Unknown SicP-binding 
domain 
Members of this family bind 
the chaperone SicP, which 
maintains effector stability and 
ensures effector secretion. 
 
BopC Yes Unknown Unknown Unknown 





Members of this family 
contain a C-terminal guanine 
nucleotide exchange factor 
domain of the Salmonella type 
3 secretion system effector 
SopE.  This effector activates 
Rho family GTP-binding 
protein-dependent signaling 
cascades to induce 
cytoskeletal rearrangements. 
 
BapA Yes Unknown Unknown Unknown 




Carrier of growing fatty acid 
chain bound to a 
phosphopantetheine prosthetic 
group covalently bound to a 
serine residue during fatty acid 
biosynthesis. 
BapC Unknown Unknown Lytic 
transglycosy-
lase domain 
Members of this family 
include lytic transglycosylases 
in bacteria, bacteriophage 
lambda and eukaryotic 
lysozymes.  Lytic 
tranglycosylases catalyze 
cleavage of β-1,4-glycosidic 
bond between N-





DISCUSSION AND FUTURE DIRECTIONS 
 
In these studies, we present results that greatly contribute to our overall 
knowledge of the pathogenesis of B. pseudomallei in mammalian hosts.  Specifically, we 
demonstrate the importance of an effective lung-specific mouse model of respiratory 
melioidosis for the development of human-like melioidosis in mice.  We identified the 
type 3 secretion system cluster 3 as critically required for respiratory melioidosis and 
other novel virulence determinants needed for B. pseudomallei lung colonization.  
Further, we found that the T3SS3 effector proteins BopA, BopC, BopE, BapA and BapC 
act in concert to mediate intracellular survival of B. pseudomallei in host cells.  Yet, these 
studies also raise additional questions that can further our understanding of host-B. 
pseudomallei interactions.  Accordingly, the following future directions could add to our 
understanding of T3SS3 effectors to the intracellular survival of B. pseudomallei in 
mammalian hosts. 
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6.1 Identification and efficacy evaluation of potential Burkholderia pseudomallei 
vaccine and therapeutic candidates using intubation-mediated intratracheal 
instillation 
Herein we show that direct delivery of B. pseudomallei to mice lungs through 
tracheal intubation, leads to a course of disease with key hallmarks of human melioidosis 
in mice, specifically development of respiratory melioidosis and septicaemic disease 
[138].  This infection model provides a strong platform for studying the pathogenesis of 
B. pseudomallei in humans, has great implications for identifying potential vaccine 
and/or therapeutic candidates against B. pseudomallei infection and for evaluating the 
efficacy of these potential candidates.  Commonly used intranasal and aerosol inoculation 
mouse models of B. pseudomallei generally result in colonization of the upper respiratory 
tract by deposition of bacteria in the nasal cavity [64, 139].  This leads to 
overrepresentation of neurological symptoms and incomplete disease progression with 
reduced spread of the bacterium to secondary sites of infection [140] and premature 
mortality in mice by suffocation [138].  Consequentially, it may be questionable to assess 
therapeutic protection against suffocation end points that likely do not elicit a complete 
immune response.  Thus, inhalational and aerosol mouse models of melioidosis do not 
model human disease correctly [139], raising challenges for identifying protective 
antigens for acute and chronic melioidosis.  Currently, there are no licensed vaccines 
available for the prevention of melioidosis; early diagnosis and subsequent antibiotic 
treatment are the only alternatives available for the management of B. pseudomallei 
infection [141], thus identifying vaccine candidates against the bacterium is of pressing 
concern.  
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We previously established that the type 3 secretion system cluster 3 is absolutely 
critical for respiratory melioidosis, strongly suggesting that the type 3 secretion apparatus 
and/or its associated proteins may constitute potential vaccine and/or therapeutic targets.  
However, a live attenuated mutant in the type 3 needle tip protein BipD and vaccination 
with purified BipB, BipC or BipD, did not confer protection against B. pseudomallei 
intraperitoneal challenge in BALB/c mice [53, 104].  We previously showed that 
different routes of infection lead to altered disease outcomes [138], accordingly, 
reevaluating protection and efficacy of these subunit vaccines in our lung-specific mouse 
model of infection, which is associated with respiratory and septicaemic melioidosis 
rather than suffocation end points, is appropriate.   
Alternatively, T3SS3 structural components and associated effector proteins may 
constitute potential therapeutic targets.  Given that the T3SS3 is critically required for the 
intracellular life cycle of the bacterium [38], it is possible that T3SS3 associated proteins 
may not be accessible to humoral immune responses.  By developing therapeutics that 
may hinder the functions of T3SS3 key proteins or may compete for binding with target 
host cell interaction partners resulting in significant bacterial attenuation, we may be able 
to reduce the morbidity and mortality associated with acute melioidosis, prevent the onset 
of chronic melioidosis or patient relapse. 
 
6.2 Tn-Seq screen: A source of novel virulence determinants 
We used IMIT in combination with transposon mutagenesis to identify novel 
virulence factors required by B. pseudomallei to colonize the mouse lung and to spread to 
the liver and spleen; all key sites of infection.  Our Tn-Seq screen identified 548 genes 
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required for respiratory melioidosis and of those ~512 were not associated with the 
capsular polysaccharide operon, the type 3 secretion system cluster 3 or the type 6 
secretion system cluster 5.  The identified genes comprised 33 genetic loci, or gene 
clusters with significant negative fold-changes (>15) located no more than a 4-gene 
distance from adjacent hits, required for respiratory melioidosis.  Numerous loci 
identified possess functions related to metabolic processes during host infection, and 
experienced significant negative fold-changes, suggesting that genes in these loci are 
critical for bacterial survival in mammalian hosts.  Specifically, genes encoding for 
proteins that function in histidine, purine, amino sugars, secondary metabolites, fatty acid 
and glycan biosynthesis among other cell wall components, experienced significant 
negative fold-changes (>150), demonstrating a compelling requirement of these genes for 
intracellular B. pseudomallei growth.  Importantly, the histidine biosynthetic pathway is 
only present in bacteria, archaea, fungi and plants [142], making this genetic cluster an 
attractive virulence determinant for attenuation and therapeutic studies.  Furthermore, 
amino sugars generated in the histidine biosynthetic pathway, may also constitute 
potential targets for aminoglycosides, inhibiting downstream metabolic pathways that 
utilize these amino sugars and are critical for B. pseudomallei in vivo growth.  Other 
potential virulence determinants that may represent suitable targets for attenuation studies 
include clusters involved in purine and secondary metabolite biosynthesis, loci almost 
completely made up of hypothetical proteins and those that encode for surface expressed 
proteins, which may be induced during various stress conditions such as early stages of 
cell growth.  Given the heterogeneity of host-pathogen interactions of B. pseudomallei in 
the host lung, it is likely that numerous virulence systems contribute to the bacterium’s 
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pathogenesis at this key site, thus validating those virulence determinants involved in 
bacterial biosynthetic process that may hinder the growth of B. pseudomallei in vivo, may 
confer great advantages for prevention against B. pseudomallei morbidity and mortality. 
 
6.3 Potential role of BopE in apoptosis inhibition through activation of the RAB45 
GTPase 
BopE is a T3SS3 effector protein with a guanine nucleotide exchange factor 
(GEF) domain [48] and is required for full virulence of B. pseudomallei in cultured 
macrophages.  The BopE homologues and T3SS Salmonella effectors, SopE and SopE2, 
also exhibit GEF activity and target the mammalian Rho GTPases Rac1and Cdc42, 
facilitating Salmonella invasion of epithelial cells [130].  BopE also exhibits GEF activity 
for Rac1 and Cdc42 but to a lower extent and notably, B. pseudomallei is not an invasive 
pathogen.  Accordingly, we hypothesize that BopE may target other host GTPases 
involved in cellular pathways, such as RAB proteins involved in vesicular trafficking, 
which are exploited by numerous intracellular pathogens [143].  Although our initial 
hypothesis was that BopE directly contributes to the rapid escape of B. pseudomallei 
from endocytic vesicles by targeting yet known host proteins located in the Burkholderia-
containing vacuolar membrane, a recent B. mallei yeast two-hybrid screen identified the 
RAB45 GTPase among other murine proteins, as a potential host cell target for BopE 
[132].  RAB45 is a newly identified small GTPase of the Ras superfamily of small 
GTPases [144] and its expression results in the activation of apoptosis in a human chronic 
myelogenous leukemia cell line by inducing phosphorylation of the mitogen-activated 
kinase p38, which leads to enhanced processing of caspase-3 and caspase-9, and 
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subsequent induction of apoptosis during cellular stress [145].  The RAB45 GTPase fits 
the profile of a potential BopE target, as this T3SS3 effector exhibits guanine nucleotide 
exchange factor activity [48] and the potential interaction of BopE and RAB45 may 
inhibit activation of the GTPase by blocking guanine nucleotide exchange, which may 
result in decreased phosphorylation of p38 and ultimate inhibition of apoptosis (Figure 
26).  Accordingly, inhibition of programmed cell death by BopE may be a significant 
benefit for B. pseudomallei as it provides the bacteria with time to establish a replicative 
niche inside host cells.  This hypothesis is supported by the growth kinetics of the bopE 
mutant in infected macrophages, which showed a peak in intracellular numbers for this 
strain at approximately 9 hours post-infection, about 2 hours before the bopA mutant 
numbers reached a peak, suggesting that programmed cell death may be inhibited or 
delayed in the presence of BopE.  Accordingly, validating RAB45-BopE interaction and 
evaluating the guanine nucleotide turnover kinetics of BopE would elucidate a potential 
role for this effector to B. pseudomallei infection.  Importantly, assessing the role of 
RAB45 during B. pseudomallei colonization would elucidate a novel mechanism of 
apoptosis inhibition by a bacterial pathogen.   
 
6.4 BapC may modify the Burkholderia pseudomallei cell wall during infection of 
host cells facilitating T3SS3 apparatus assembly  
The T3SS3 effector BapC is a small 187-amino acid residue protein with 
predicted amino-terminal transmembrane and lytic transglycosylase domains, and is 
required for intracellular fitness of B. pseudomallei.  Lytic transglycosylases are bacterial 
enzymes characterized as “space-making” autolysins that cleave the β-1,4 glycosidic 
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bonds between N-acetylmuramic acid and N-acetylglucosamine resulting in non-reducing 
1,6-anhydro bonds in N-acetylmuramic acid peptides [146].  Lytic transglycosylases have 
been shown to be involved in insertion of bacterial cell-wall spanning structures such as 
pili, flagella and secretion systems; peptidoglycan biosynthesis and recycling; cell 
division and maintenance of bacterial morphology [147].  These autolysins have been 
implicated in the pathogenicity of several Gram-negative bacteria such as 
enterohemorrhagic E. coli (EHEC) and Neisseria gonorrhoeae [148, 149] and have been 
found in the T3SS and type 4 secretion system (T4SS) locus of Burkholderia cepacia, 
enteropathogenic and enterohemorrhagic E. coli, S. enterica, S. flexneri, Yersinia 
enterocolitica, Brucella suis, Agrobacterium tumefaciens and other bacterial pathogens 
[146].  Accordingly, BapC may function as a lytic transglycosylase in the bacterial 
periplasmic space during B. pseudomallei infection of host cells.  Thus, we hypothesize 
that BapC may modify the bacterial cell wall, creating a pore for rapid T3SS3 apparatus 
assembly and passage through both bacterial membranes (Figure 26).  Yet, inactivation of 
bapC results in a moderate defect in B. pseudomallei survival, suggesting that other B. 
pseudomallei lytic transglycosylases may complement the loss of bapC.  BapC was 
recently shown to be secreted in vitro in a T3SS3-dependent manner [55], yet this finding 
contradicts a T3SS3 secretome screen, which did not identify BapC as a T3SS3-secreted 
effector [54].  To date, the potential mechanisms of delivery of T3SS-associated lytic 
transglycosylases to the periplasmic space remain relatively unknown, although some 
lytic transglycosylases have been shown to encode an amino-terminal periplasmic signal 
peptide sequence and are transported into the periplasmic space in a sec-dependent 
manner [148, 150].  Further, the Brucella sius and A. tumefaciens T4SS-associated lytic 
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transglycosylase VirB1 has been shown to transiently associate with T4SS apparatus 
components, potentially providing chaperone activity for apparatus components and 
traversing the bacterial inner membrane into the periplasm where it may mediate 
apparatus assembly [150, 151].  Thus, it may be possible that BapC is transported into the 
periplasm of B. pseudomallei through the general secretory pathway or by associating 
with apparatus components permitting transport of the effector to the periplasm.  
Therefore, identifying a potential periplasmic signal peptide sequence at the protein’s 
amino terminal is of pressing concern.  The predicted peptidoglycan pore size allows for 
diffusion of globular proteins with a molecular weight of ~55 kDa or less [151] and 
BapC, with a predicted 20.2 kDa molecular weight would easily diffuse through the 
periplasmic space allowing the potential docking of BapC to either the inner or outer 
membrane.  Accordingly, identifying the subcellular distribution of BapC in the 
bacterium and importantly, validating BapC transglycosylase activity with the B. 
pseudomallei sacculus would provide great insight into BapC functions during infection 
and its modulation of B. pseudomallei peptidoglycan dynamics in vivo. 
 
6.5 Induction of pyroptotic and/or apoptotic cell death during Burkholderia 
pseudomallei infection of host cells 
The growth profile of the parental B. pseudomallei strain JW280 illustrates that 
early in the course of infection, bacterial numbers are significantly reduced (Figure 18).  
This decrease can be partially attributed to extracellular bacterial killing of gentamicin 
added to the culture medium, but in our hands, synchronized infection of macrophages by 
centrifugation leads to ~60% of bacterial inoculum internalization by 15 minutes post 
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infection, which implies that infected macrophages also contribute to the decline in 
bacterial numbers by killing intracellular B. pseudomallei.  Yet, early killing of B. 
pseudomallei by infected macrophages is not 100% effective in eradicating the 
bacterium, suggesting that infected cells must resort to other methods of controlling 
intracellular B. pseudomallei numbers.  Cell autonomous immune responses of 
macrophages against B. pseudomallei includes the induction of pyroptotic cell death 
through activation of caspase-1, which takes place early during the course of infection 
and seems to be dependent on bacterial strain and intracellular bacterial burden [152].  
Yet B. pseudomallei can also induce apoptotic cell death in host cells [153] by 
mechanisms yet unknown.  We previously hypothesized that potential induction of 
apoptosis may take place through activation of the MAP kinase p38 as a result of BopE-
RAB45 interaction.  Yet, activation of p38 and the outcome of this activation has been 
shown to be cell type and stimulus dependent [154].  Our Tn-Seq findings showed that B. 
pseudomallei colonizes and replicates in the lungs of mice as early as 6 hours post 
infection, but bacterial numbers in the liver remain relatively the same by 24 hours post 
infection [155], suggestive of altered immune responses associated with different cell 
types.  Accordingly, we hypothesize that several mammalian cell types may harbor B. 
pseudomallei infection in vivo and these host cells may undergo pyroptotic or apoptotic 
cell death depending on the bacterial stimuli encountered.  To address this hypothesis, 
first we would need to define the repertoire of mammalian cells that may harbor B. 
pseudomallei infection in vivo using our lung-specific mouse model of infection and 
analyze single cell suspensions from infected lungs, liver and spleen labeled with distinct 
cell surface markers using flow cytometry.  Once the B. pseudomallei host cell repertoire 
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is defined, we have the ability to assess the role of specific caspases in inducing 
pyroptotic and/or apoptotic cell death at early or late time points in infection using our 
real time high throughput assay and in vivo optical diagnostic imaging.  Results from 
these assays will further our knowledge of the pathogenesis of B. pseudomallei in vivo, 
would elucidate appropriate cell-autonomous immune responses against various B. 
pseudomallei stimuli and provide potential cell targets for therapeutics against infection 




Figure 26.  Model of the potential functions of T3SS3 effectors BopA, BopE and 
BapC during Burkholderia pseudomallei infection of host cells.  Modification of the 
bacterial cell wall by BapC may facilitate passage of the T3SS3 needle through both 
bacterial membranes and peptidoglycan.  BopA binding to TRAPPC8 may inhibit vesicle 
expansion also leading to vacuolar destabilization and the rapid escape of B. 
pseudomallei from the vacuole.  Potential BopE interaction with the GTPase RAB45 may 
lead to inhibition of apoptotic cell death, providing B. pseudomallei the time required to 
establish a replicative niche in the cytoplasm of the host cell.  Other T3SS3 translocated 
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Graduate Research Assistant       2012 – Present        
Department of Microbiology and Immunology, University of Louisville 
Dissertation Chair: Jonathan M. Warawa, Ph.D.              
Project: Characterize the role of the Tier 1 Select Agent Burkholderia 
pseudomallei Type 3 Secretion System effector proteins in mediating viability of 
the bacterium in a lung-specific mouse model of disease and in macrophage cell 
culture models. 
  
• Planned, carried out and analyzed experimental results to determine attenuation 
level, differential phenotype and trafficking pattern associated with distinct B. 
pseudomallei mutant strains in in vitro and in vivo disease models. 
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• Maintained B. mallei and B. pseudomallei Select Agent inventories and BSL-3 
and ABSL-3 laboratory spaces in compliance with CDC and APHIS Biological 
Select Agent And Toxins regulations. 
• Resolved technical problems associated with in vitro and in vivo scientific 
protocols, procedures and equipment. 
• Prepared study protocols, spreadsheets, charts, graphs, presentations and 
manuscripts to communicate experimental work flow and results to both scientists 
and the general public. 
 
Graduate Research Assistant              Spring 2012 - Fall 2012         
Department of Microbiology and Immunology, University of Louisville 
Mentor: Silvia M. Uriarte, Ph.D.                        
Project:  Investigate the effects of fusion proteins of the HIV-1 cell penetrating 
TAT peptide and the synaptobrevin domain of the mammalian Vesicle-Associated 
Membrane Proteins (VAMP) -3 and -8 on human neutrophil degranulation. 
 
• Planned, carried out and analyzed experimental results to determine the inhibitory 
effects of TAT-VAMP-3 and TAT-VAMP-8 fusion proteins on human neutrophil 
degranulation using flow cytometry. 
• Prepared presentations, spreadsheets and graphs to communicate weekly 
experimental results related to on-going experiments. 
• Trained and assisted graduate and undergraduate students in on-going laboratory 
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Undergraduate Research Assistant      Summer 2010 Lung 
Biology Center, University of California San Francisco   
Mentor: David Erle, M.D.                
• Investigated expression of the secreted polymeric mucin MUC5AC and the 
protein disulfide isomerase AGR2 in airway epithelial cells of allergen-challenged 
mice. 
• Prepared both oral and written presentations to communicate weekly experimental 
findings. 
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Mentor: Tom Huxford, Ph.D.         
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